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INTRODUCTION AND LITERATURE REVIEW 
1.1.  Introduction 
Glutamate was proposed as a central nervous system synaptic transmitter in the 1950s 
because of its capability of causing convulsions and exciting central neurons (Hayashi, 
1952; Curtis et al., 1959; Curtis et al., 1972). Despite this evidence, glutamate was not 
considered a specific transmitter, since it seemed to excite every neuron when tested and 
it was not accepted as an excitatory neurotransmitter until the late 1970s (Duggan and 
Johnston, 1970; Krnjevic, 1970; Martin et al., 1970).  Glutamate is now recognized to be 
the major excitatory neurotransmitter in the vertebrate central nervous system. Glutamate 
receptors are expressed throughout the central nervous system as well as some peripheral 
tissues (Egebjerg et al., 1991). There are two major classes of glutamate receptors, 
metabotropic and ionotropic. Metabotropic glutamate receptors (mGluR1-mGluR8) 
signal via G-protein Galpha(q/11) or Galpha(i) signaling cascades (Inagaki et al., 1995; 
Weaver et al., 1996; Chenu et al., 1998; Patton et al., 1998), while ionotropic glutamate 
receptors are ligand-gated ion channels. 
Three physiologically and pharmacologically distinct families of glutamate gated ion 
channels have been described and named after their selective agonists: N-me hyl-D-
aspartic acid (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropioic acid (AMPA) 
and kainate. Among these, AMPA receptors mediate the majority of excitatory 
neurotransmission in the central nervous system. NMDA receptors are also primarily 
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found post-synaptically and play a major role in synaptic plasticity (Malenk a d Bear, 
2004). Kainate receptors play a lesser role in synaptic signaling and plasticity and they 
are primarily located pre-synaptically (Huettner, 1990).  
NMDA receptors are tetramers of NMDAR1, NMDAR2A-D and NMDAR3A 
subunits with preferred stoichiometry of two NR1 and two NR2 subunits (Behe et al., 
1995). AMPA receptors are tetramers of pore-forming subunits GluR1-4, encoded by 
four genes GRIA1-4 respectively (Boulter et al., 1990; Keinanen et al., 1990), that co-
assemble with auxiliary subunits of the transmembrane AMPA receptor regulatory 
protein family (TARPs) (Tomita et al., 2003) or cornichons (Schwenk et al., 2009). 
Kainate receptors form tetrameric assemblies consisting of KA1-2 and GluR5-7 subunits, 
encoded by five genes GRIK1-5 respectively (Hollmann et al., 1989). Structural relatives 
of ionotropic glutamate receptors δ1 and δ2 receptors are encoded by 2 genes GRID1-2 
(Lomeli et al., 1993). Because δ1 and δ2 neither bind glutamate, nor form functional 
channels when expressed alone, their role in the CNS function remains unknown. 
NMDA, AMPA and kainate receptor subunits do not co-assemble together to form 
functional channels (Brose et al., 1994; Patneau et al., 1994). 
1.2 Structure and function of the AMPA receptor pore-forming subunits 
1.2.1 Identification and cloning. 
Original studies on native AMPA receptors from rat primary neuronal cultures 
concentrated on characterizing the functional properties of the receptor. In these studies, 
AMPA receptors from distinct areas of the brain elicited currents in response to 
glutamate that were primarily carried by sodium and had low permeability to calcium 
(Olsen et al., 1987; Iino et al., 1990). Early experiments also observed a striking property 
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of AMPA receptors, rapid desensitization (1-10 ms) of glutamate evoked currents to a 
small steady-state level in the continuous presence of agonist (Trussell et al., 1988; 
Mayer and Vyklicky, 1989; Patneau and Mayer, 1991; Raman and Trussell, 1992). The 
affinity of AMOA receptor for to glutamate increased 19 fold as receptor ente ed the 
desensitized state from EC50 361 µM to EC50 19 µM (Patneau and Mayer, 1990). 
The cloning of the AMPA receptor subunit GluR1 by Hollmann et. al. in 1989 opened 
new avenues for glutamate receptor research. This subunit was first identifie  as GluR-
K1 with sequence homology to that of a previously identified kainate binding protein of 
the chick and frog (Hollmann et al., 1989). This cloned subunit was able to form 
functional channels when injected into Xenopus Oocytes and were gated by both 
glutamate and kainate. Interestingly, these homomeric channels were calcium permeable, 
which contradicted previous data from neuronal cultures, where the majority of AMPA 
receptors were calcium impermeable (Keinanen et al., 1990). Further investigation led to 
cloning of three more cDNAs encoding 900-amino acid AMPA receptor subunits with 
approximately 70 percent sequence homology termed GluR2 – 4 (Boulter et al., 1990; 
Keinanen et al., 1990).  
Detailed electrophysiological analysis of recombinant AMPA receptors led to 
identification of two distinct rectification patterns that were coincidentally correlated with 
calcium permeability. Channels composed of GluR1, GluR3 or GluR4 subunits all 
showed a doubly rectifying pattern (i.e., the channels were unable to conduct curren in 
an outward direction when the holding potential was positive) and were calcium 
permeable, while channels containing a GluR2 subunit showed simple outward 
rectification (i.e., the channels were able to conduct current in both directions, inward and 
 4
outward, when the driving force was changed accordingly) and had low calcium 
permeability. Sequence comparison revealed a post-transcriptionally modified site in the 
pore domain of GluR2 that was subjected to RNA editing (Verdoorn et al., 1991). This 
single Q/R amino acid exchange is responsible for the specific electrophysiological 
properties of GluR2 containing AMPA receptors, which include a linear current-voltage 
relationship, low calcium permeability and low single channel conductance (Swanson et 
al., 1996). Linear current-voltage relationship and low calcium permeability are dominant 
in heteromeric assemblies of AMPA receptors containing GluR2 (Hume et al., 1991; 
Verdoorn et al., 1991; Egebjerg and Heinemann, 1993).  
The topology of glutamate receptors differs from that of other ligand-gated ion 
channels. AMPA receptors possess an extracellular N-terminus, intracellul r C-terminus, 
three transmembrane (TM) domains, TM1, TM3 and TM4, and a channel lining re-
entrant membrane segment TM2 (see Figure 1.1) (Hollmann et al., 1994; Bennett and 
Dingledine, 1995; Seal et al., 1995). 
Detailed analysis of cDNAs encoding all four AMPA receptor subunits reveal d a 
115 base pair segment conserved throughout the AMPA receptor family, that encodes for 
38 amino acid residues within a domain preceding transmembrane region 4 (TM4). This 
segment occurs in two alternative versions named “flip” and “flop”, arising from 
alternative splicing (Sommer et al., 1990) (illustrated in Figure 1.1). The versions are 
very similar, with most nucleotide substitutions being silent changes in respect to pro ein 
sequence, differing in only 9 amino acids. These two alternative versions of the protein
show a distinct pattern of expression in the brain and a different desensitization profle.
Flop receptors desensitize more rapidly and profoundly than flip receptors, revealing the 
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importance of the flip/flop region as a regulatory point in molecular and functional 
properties of AMPA receptors (Sommer et al., 1990). 
Analysis of the exon – intron organization of the RNA of AMPA receptors led to the 
discovery of differences in the C-terminus coding sequence arising from alternative 
splicing. C-terminal splice variants are found in GluR2 and GluR4 subunits that exist 
both in long and short C-terminus forms (illustrated in Figure 1.1) (Gallo et al., 1992; 
Kohler et al., 1993). Functional differences between short and long AMPA receptor 
splice variants have not been reported. The different length of the C-terminal tail, 
however, may play a role in binding different intracellular proteins, leading to a different 
pattern of receptor expression and membrane targeting (Osten et al., 1998). 
 
 
Figure 1.1: AMPA receptor splice variants, editing sites and topology. Schematic 
representation of the AMPA receptor protein sequence  with alternative splicing and 
RNA editing sites (A) and Schematic illustration of AMPA receptor topology (B). From 





AMPA receptors are crucial for brain function and development and thus it is 
imperative to have mechanisms to control AMPA receptor functional properties, 
trafficking and expression. These control mechanisms include differential splicing and 
RNA editing to create a diversity of AMPA receptors with distinct kinetic, 
pharmacological and expression profiles, that are imperative for normal brain function.  
1.2.2 Post-Translational Modification 
The AMPA receptor protein undergoes post-translational modifications including N-
linked glycosylation and phosphorylation at specific sites (Hollmann et al., 1994; 
Kawamoto et al., 1995; Roche et al., 1996; Mammen et al., 1997). The C-terminus of the 
AMPA receptor contains a number of consensus sites for phosphorylation, including 
phosphokinase A (PKA), calcium/calmodulin-dependent protein kinase II (CAMKII) and 
phosphokinase C (PKC) (Roche et al., 1994; Mammen et al., 1997). 
N-linked glycosylation of AMPA receptors is imperative for both channel activity 
and their modulation by lectins. When glycosylation is prevented using tunicamycin, the 
molecular mass of GluR1 and GluR2 subunits is decreased by 4 kDa, indicating that 
AMPA receptors contain 4 to 6 N-glycosylation sites (Everts et al., 1997). The 
unglycosylated form of the receptor does not bind [3H]AMPA (Kawamoto et al., 1995) 
and the maximal amplitude of kainate induced currents mediated by GluR1flop in HEK 
cells is reduced by fifty percent (Hollmann et al., 1994). These results demonstrate that 
N-linked glycosylation of AMPA receptors is important for the formation and 




1.2.3 AMPA receptor pharmacology 
AMPA receptor agonists are found in two major chemical classes based on homology 
of their structure to either AMPA or the willardiines. The class of AMPA receptor full 
agonists includes glutamate, AMPA and quisqualate, while kainate and willardiine 
derivatives are only partial agonists. In addition, several potent neurotoxins including 
domoic acid from dinoflagellates and beta-N-methylamino-L-alanine from cycad seeds 
are powerful AMPA receptor agonists. No agonists have been identified that exhibit 
selectivity for particular AMPA receptor subunit combinations.  
AMPA receptor currents can be potentiated by positive allosteric modulat rs. Such 
modulators impede receptor desensitization and include benzodiathiazines such as 
cyclothiazide and IDRA21 (Yamada and Rothman, 1992; Patneau et al., 1993; Yamada 
and Tang, 1993; Thompson et al., 1995; Zivkovic et al., 1995), pyrrolidinones such as 
aniracetam (Ito et al., 1990; Isaacson and Nicoll, 1991; Vyklicky et al., 1991), and the 
AMPAkines such as BCP and BDP (Desai et al., 1995; Arai et al., 1996). These different 
classes of drugs have a similar effect of slowing the decay of excitatory post-synaptic 
potentials (EPSP), thereby increasing efficacy of glutamatergic synaptic transmission. 
These compounds are highly selective for AMPA receptors, although their effects ar  
different with alternatively spliced flip/flop region in the M3-M4 loop domain (Cotton 
and Partin, 2000). 
AMPA receptor antagonists have been synthesized and studied for their possible 
therapeutic benefit in ischemic stroke and excitotoxic disorders like ALS. Antagonists are 
divided into three categories: competitive antagonists that bind at the glutamate binding 
site; open channel blockers that block the ion pore; and non-competitive antagonists that 
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inhibit AMPA receptor function while binding at a site distinctly different from 
glutamate. The most effective competitive blockers of AMPA receptors were synthesized 
from compounds in quinoxalines and quinoxalinediones families, including CNQX, 
DNQX, NBQX and PNQX (Honore et al., 1988; Sheardown et al., 1990; Bigge et al., 
1995).  
AMPA receptor channel block by natural toxins, including argiotoxin and Joro spider 
toxin, and endogenous polyamines are dependent on the Q/R site editing of the M2 lining 
the ion channel pore. These small positively charged molecules are attracted to th  
negatively charged residues in the ion pore, while being repelled by the positively 
charged arginine present in GluR2 (Kawai et al., 1982; Magazanik et al., 1997; Williams, 
1997).  
AMPA receptor selective non-competitive antagonists include another class of drugs, 
2,3-benzodiazepines (Buchan et al., 1993; Donevan and Rogawski, 1993; Zorumski et al., 
1993; Fletcher and Lodge, 1996). In contrast to their 1,4 analogues, 2,3-benzodiazepine 
derivatives have no affinity for GABA receptors (Zappala et al., 2001). GYKI 52466 (1-
(4-aminophenyl)-4-methyl-7,8-methyl-enedioxy-5H-2,3-benzodiazepine) was initially 
shown to act as a muscle relaxant (Tarnawa et al., 1990). Subsequent experiments 
demonstrated that GYKI 52466 and the related GYKI 53655 (1-(4-aminophenyl)-3-
methylcarbamyl-4-methyl-7,8-methylenedioxi-3,4-dihydro-5H-2,3-benzodiazep ne) are 
highly selective, non-competitive antagonists of AMPA receptors, and as such co ld have 




1.2.4 Receptor stoichiometry and assembly. 
Ionotropic glutamate receptors are multisubunit assemblies organized around a 
central ion conducting pore. Two studies in 1998 provided support for a tetrameric 
structure of the pore-forming subunits (Mano and Teichberg, 1998; Rosenmund et al., 
1998). Rosenmund et. al. assumed that each of the subunits contains a functional binding 
site and that the number of binding sites is equal to the number of subunits in receptor 
assembly. Channel conductances observed as a result of agonist binding proceeded in a 
“staircase” fashion through 3 distinguishable conductance states (small = 5 pS, medium = 
15 pS and large = 23 pS). By measuring the time the receptor spent in each conductance 
state, it was clear that the transition between the closed and smallest conductance state 
was twice as long as the transition between the small and medium or medium an  large 
conductance states. This is in agreement with pharmacological studies indicating th  two 
molecules of agonist must bind to open the channel (Patneau and Mayer, 1990). 
Unlike nicotinic receptors, that assemble in predetermined fashion (Kubalek et al., 
1987), AMPA receptor assembly is poorly understood and there is no obligatory subunit 
stoichiometry. However it has been shown that differential subunit assembly controls 
functional properties, trafficking (Barry and Ziff, 2002; Bredt and Nicoll, 2003) and 
synaptic targeting of native receptors (Gardner et al., 2001). This subunit composition 
also plays a crucial part in synaptic plasticity and efficacy (Malinow, 2003).  
Early experiments in co-expression of GluR1 or GluR2 in edited (R) and unedited (Q) 
forms suggested that homomeric receptors assembled stochastically, while heteromeric 
receptors preferentially formed with a stoichiometry of two GluR1 and two GluR2 
subunits, with identical subunits positioned on opposite sides of the channel pore (Stern-
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Bach et al., 1994; Mansour et al., 2001). Further studies suggested that composition of 
AMPA receptors is not static but can be altered in response to certain stimuli. I  is unclear 
which properties and/or modifications of AMPA receptors are crucial for the ass mbly 
process. Several possibilities have been described in the literature, including involvement 
of the GluR2 subunit, Q/R editing site and flip/flop cassette (Stern-Bach et al., 1994; 
Mansour et al., 2001; Greger et al., 2003; Brorson et al., 2004).  
Several studies indicate that the N-terminal domain (NTD) of AMPA receptors is also 
involved in heteromeric receptor assembly (Leuschner and Hoch, 1999; Ayalon and 
Stern-Bach, 2001). The AMPA receptor NTD, which is composed of approximately 400 
amino acids and is homologous to bacterial periplasmic protein (Jin et al., 2009), has 
been recently crystallized. Data suggest that dimerization of the NTDs has to occur 
before AMPA receptor dimers can form, therefore contributing to AMPA receptor 
assembly (Ayalon et al., 2005; Jin et al., 2009). 
1.2.5 Ion pore structure. 
AMPA receptor topology differs from that of the superfamily of the cys-loop ligand-
gated ion channels, but is similar in structure to that of potassium channels. Based on this 
observation, early modeling of AMPA receptor gating was done on the basis of 
homology with potassium channels, which have a 4-fold symmetry in the pore with a 
rigid TM3 that does not move during gating. The narrowest part (the innermost part) of 
the AMPA receptor channel is lined by the residues that lie shortly after the turn of the 
alpha-helix in the TM2 re-entrant segment. The Q/R site is located downstream of the 
apex of the re-entrant loop, forming the selectivity filter of the channel (Seburg et al., 
2001). The outer part of the pore is lined by the residues from TM3 which contains a 
 11
motif conserved through all AMPA receptors – SYTANLAAF (Figure 1.2) (Sobolevsky 
et al., 2004).  
 
Figure 1.2: Graphical representation of the glutamate receptor ion pore. (From 
Sobolevsky, 2004) 
 
Cysteine scanning mutagenesis in both TM3 and TM2 that line the ion pore identified 
an interesting fact. The segments of TM3 deep inside the pore as well as the 
corresponding segment on the extracellular face of the pore move simultaneously, 
suggesting that the entire TM3 segment of AMPA receptors moves during receptor 
gating. The outermost part of TM3 contributing to the channel operates in concert with 
the adjoining TM3 of another subunit in a dimer, thus following a 2-fold symmetry 
(Sobolevsky et al., 2004). Therefore, unlike potassium channels, the AMPA receptor has 
a highly movable TM3 and a 2-fold symmetry for the outer segment of the pore. It is 





1.3 Additional structure and gating mechanisms learned from the AMPA 
receptor crystal structure 
1.3.1 Ligand-binding core 
Sequence comparisons revealed that mammalian glutamate-gated ion channels ve 
regions of weak sequence homology with the bacterial periplasmic amino acid binding 
protein (QBP). The structure of QBP has been solved and was known to include two 
lobes separated by a cleft. This structure suggested a “venus fly-trap” model in which 
glutamate binds and forces closure of the binding site around itself (Nakanishi et al., 
1990).  
In an attempt to identify the binding domain of glutamate receptors, several studies 
paved the way for future receptor crystallization. Performing exchange of portions of the 
AMPA receptor subunit GluR3 and the kainate receptor subunit GluR6, two segments of 
interest were identified (Stern-Bach et al., 1994). They were each approximately 150 
amino acids long and were responsible for agonist pharmacology of these chimeric 
receptors. The first segment (S1) is adjacent and N-terminal to TM1, whereas the second 
segment (S2) consists of the extracellular loop between TM3 and TM4. Only 
simultaneous exchange of S1 and S2 converted the pharmacological profile of the 
recipient receptor to that of the donor receptor (Stern-Bach et al., 1994). A later
investigation demonstrated that deletion of the first 400 amino acids of the N-terminal 
domain (NTD) and the C-terminal 90 amino acids from GluR6 left a membrane-bound 
core homomeric receptor that displayed normal [3H]kainate binding properties (Keinanen 
et al., 1998). Based on this work, a subsequent study demonstrated that constructs 
containing GluR2 S1 and S2 domains joined by a short linker of 13 amino acids could be 
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expressed in insect and bacterial cells and were capable of binding agonist with affinities 
similar to that of native receptors (Arvola and Keinanen, 1996). These studies defined the 
ligand-binding core of glutamate receptors and confirmed homology of the ligand-
binding core structure of the glutamate receptor to that of the QBP “venus fly-trap” 
model of agonist binding. These studies also facilitated crystallization of glutamate 
receptors. 
Crystallization of any membrane-bound protein is complicated by its low 
concentration in the plasma membrane. Creation of the construct containing S1 and S2 
domains joined by a short linker that was secreted from bacterial cells and could be 
purified and concentrated finally made crystallization of a crucial portion of an AMPA 
receptor possible. The high-resolution crystal structure (approximately 1.9 Å) of GluR2 
S1-S2 “flop” protein bound to kainate was resolved via X-ray diffraction. The bilobed 
structure had a striking resemblance to QBP and possessed a clamshell-like shape with 
agonist bound in the cleft between the two halves of the clamshell (Figure 1.3) 
(Armstrong et al., 1998). Interestingly, some crystals formed dimers with their ligand 
binding domains facing outwards, conforming to a 2-fold symmetry model. This model 
implies that the ligand-binding domains of two subunits operate in concert (Armstrong 
and Gouaux, 2000; Sun et al., 2002). 
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Figure 1.3: Schematic of the GluR2 subunit used to crystallize the ligand-binding 
domain of the protein (Armstrong et al., 1998) 
 
According to the crystal structure, the S1-S2 protein has two domains arranged in th  
shape of a kidney with domains one and two mainly composed of S1 and S2 segments 
respectively. Helixes of the S1-S2 domains are lettered A – K while the loops are 
numbered 1 – 2. S1 crosses over S2 and ends in domain 2, while the distal portion of S2 
contributes to domain 1 (Armstrong et al., 1998). The two domains are connected by two 
β strands each composed of 3 residues: Met496 – Leu498 and Lys730 – Tyr732. 
Proteolysis studies of S1-S2 bound to glutamate identified regions important for ligand
binding. Regions resistant to proteolysis Gly499 – Pro507 and Pro632 – Lys641 are 
crucial to agonist binding and when deleted abolish agonist binding altogether. Regions 
susceptible to proteolysis Gln508 – Glu524, Glu627 – Ser631 and Gly776 – Asn791 do 
not participate in agonist binding and when deleted have no effect on agonist binding 
(Chen et al., 1998). The crevice for kainate and glutamate binding is formed between S1 
and S2 by four helixes D, F, H and I (illustrated in Figure 1.4). Two residues, Glu402 and 
Tyr686, are crucial for agonist binding but rather than directly participating in kainate 
binding, instead help hold the clamshell in the closed conformation (Armstrong et al., 
 15
1998). Kainate induces an intermediate degree of clamshell closure as compared to the 
opened and closed conformations of QBP. 
 
Figure 1.4: Helices D, F, H and I comprising the clamshell binding domain of GluR2 
S1S2 domains (Armstrong et al., 1998) 
 
Further crystal structure studies revealed that the full agonists glutamate, AMPA and 
quisqualate bring the domains of the ligand binding core approximately 21 degrees closer 
together compared to the open (apo) configuration.  This is in contrast to the partial 
agonist kainate, which induces only 12 degrees of domain closure compared to the apo 
state because of its physical interaction with residues Tyr450 and Leu650, producing 
steric hindrance that prevents full domain closure (Armstrong and Gouaux, 2000). 
Mutation of Tyr450 to smaller residues yields a non-functional ligand binding core, whil  
mutation of Leu650 to a threonine inverts the relative potency of AMPA and kainate, 
making kainate 10-fold more efficacious while making AMPA a partial agonist 
(Armstrong et al., 2003). These studies indicate that the glutamate receptor ligand-
 16
binding domain can adopt a range of conformations dependent on the specific ligand 
bound, and that the conformational change determines whether a ligand is a full agonist,
partial agonist or antagonist.  
The conformational changes following agonist binding in AMPA receptors are 
complex, involving both channel opening and desensitization. A study of GluR4 S1-S2 
protein bound to glutamate indicates that the process of ligand binding consists of two 
steps: docking and locking (Mamonova et al., 2008). Docking occurs as a glutamate 
molecule binds to domain 1 of S1-S2 adjacent to residues Glu402 and Tyr450. Following 
docking the protein undergoes locking, that leads to formation of a high affinity stable
protein complex. The locking process involves formation of a hydrogen bond network 
between the agonist and the side chain of Thr480 and Glu705 as well as interaction and 
bonding of residues Glu402 and Tyr686. The locking process is thought to initiate 
channel gating, however it is hard to correlate these processes, because the S1-S2 crystal 
lacks the linker regions and actual ion channel (Abele et al., 2000). 
1.3.2 Partial agonist action 
Partial agonists are useful tools for studying the gating mechanism of the AMPA 
receptor. Historically, two models for gating of ligand-gated ion channel have been 
proposed. The two-state model (concerted transition) proposed that receptors exist in 
equilibrium between resting and active conformations (Monod et al., 1965). This model 
suggests that differences in agonist efficacy result from different relative affinities of 
agonist for resting and active conformation of the receptor. The multistate model 
(induced fit) suggests instead that the receptor can exist in multiple conformational states 
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and those ligands that best fit the receptor binding pocket produce the greatest extent of 
activation (Koshland, 1958; Koshland et al., 1966).  
Structural work on AMPA receptors suggested that domain closure, as a result of 
ligand binding, leads to opening of the ion channel and those agonists with better fit 
promoted greater closure of the ligand binding core. Further, variations in the extent of 
domain closure, as a result of agonist steric occlusion, correlated with the efficacy for 
activation of channel gating (Armstrong and Gouaux, 2000; Jin and Gouaux, 2003). In 
the case of competitive antagonists, a crystal structure of GluR2 with CNQX shows only 
a slight domain closure, a movement that is presumably not enough to open the ion 
channel (Armstrong and Gouaux, 2000). Further structural work by the same group 
elucidated principles of partial agonist action in AMPA receptor using a L650T mutation, 
that increases kainate apparent affinity 46-fold while lowering AMPA efficacy to that of 
a partial agonist. After crystallization of the construct it was apparent that domain closure 
of L650T with kainate bound increased to 15 degrees as compared to Apo state. This was 
an increase of 3 degrees compared to wild type receptor with kainate bound. However 
when the L650T mutant was crystallized with AMPA, the partial agonist in this case, the 
degree of domain closure was comparable to that of a wild type receptor with AMPA or 
glutamate bound – 21 degrees, indicating that, although AMPA was able to elicit full 
domain closure, it was unable to fully gate the channel (Armstrong et al., 2003).  Recent 
crystallographic studies with GluR2 S1-S2 indicate that binding of the partial agonists not 
only prevent full cleft closure, but also induce a twist in the protein (Bjerrum and Biggin, 
2008). Thus, the gating mechanism of the AMPA receptor is better described by 
multistate model and may involve several conformational changes different from hose 
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with full agonist bound, including graded ligand binding domain closure, protein twisting 
as well as some other unknown mechanisms.  
1.3.3 Mechanism of Desensitization 
One important feature of AMPA receptors is their rapid and profound desensitization 
in the continued presence of agonist. Figure 1.5 illustrates responses from homeric 
GluR1 receptors expressed in HEK293 cells in the presence of glutamate, kainate and 
glutamate + trichlormethiazide (TCM), a positive allosteric modulator of AMPA 
receptors that blocks desensitization. 
 
Figure 1.5: GluR1 responses to glutamate, kainate and combination of glutamate and 
trichlormethiazide. Blue bar indicates the duration of drug application. 
 
The mechanism of AMPA receptor desensitization, as shown in the response to 
glutamate above, seems to involve multiple conformational changes in AMPA receptor 
extracellular domains. Combined studies involving site-directed mutagenesis of domain 1 
and crystallization revealed a complex series of protein interactions between domains 1 
of adjacent subunits in the dimer. For example, mutation of GluR3flip L507Y (equivalent 
to L483Y in GluR2) blocks receptor desensitization by creating an additional salt bridge 
between domains 1 of the dimer (Stern-Bach et al., 1998; Sun et al., 2002). The 
importance of maintaining contacts within the dimer interface is further supported by 
evidence that the positive modulator cyclothiazide, which blocks desensitization, binds at 
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the dimer interface (illustrated in Figure 1.6), interacting with both domains of the 
AMPA receptor, thus stabilizing the open conformation (Jin et al., 2005). Site directe 
mutagenesis indicates that two critical residues of GluR3 Ser750 on helix J and Ser493 
are exposed on the dimer interface of the protein and are imperative in cyclothiazide 
binding and conferring its effect on receptor desensitization (Partin, 2001). Mutations that 
promote desensitization appear to act by introducing steric hindrance within the dimer 
interface, thus destabilizing dimer interactions, while mutations that stabilize the dimer 
interface appear to slow the onset of desensitization (Partin et al., 1994; Sun et al., 2002; 
Horning and Mayer, 2004).  
 
Figure 1.6: Mechanism of AMPA receptor desensitization onset and the action of the 
benzothiadiazine modulator. The binding of the neurotransmitter by the ligand-binding 
cores initiates channel opening and desensitization (A). Binding of the positive allosteric 
modulators across the intra-dimer interface blocks desensitization (B). 
 
Taken together, the current model of channel gating and desensitization involves 
several conformational rearrangements (illustrated in Figure 1.6). Upon agonist binding 
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the clamshell closes trapping the agonist in the cleft between domains 1 and 2. The 
energy of the agonist binding is translated into the channel opening. Simultaneously with 
channel opening, the receptor enters the desensitized state that is accompanied by the 
breaking of the protein interactions between helices J and D of opposing subunits in the 
dimer (helices are illustrated in Figure 1.7). It is presumed that the dissociation of 
domains relieves the stress on the linkers connecting S1 and S2 to the TMs and channel 
pore that opens the channel, allowing the receptor to enter into a non-conducting or a 
very low conducting state without dissociation of agonist (Sun et al., 2002). 
 
Figure 1.7: Schematic representation – side view (left) and top view (right), of AMPA 
receptor dimer interface, based on a crystal structure of L483Y in GluR2 with AMPA 
bound. 
 
Multiple protein interactions between the subunits in the dimer, including salt 
bridges, hydrogen bonds and Van der Wall’s interactions contribute to the stability of the 
dimer interface (Sun et al., 2002; Horning and Mayer, 2004). Two salt bridges spanning 
across the dimer interface connect domain 1 of each subunit. They are formed by resiues 
E486 (helix D) and K493 (helix D) in domain 1 of the adjacent subunit of a dimer. 
Mutation of these residues to alanine destabilizes the dimer interface, increasi g the rate 
of desensitization 41 fold for K493A and 10 fold for E486A. A vast network of hydrogen 
bonds supports the dimer interface, formed by residues E486 (helix D), K493 (helix D), 
N747 (helix J) and E755 (helix J), connecting helix D of one subunit with helix J of the 
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other. Mutation of these residues to alanine destabilized the dimer interface, increasing 
the desensitization rate 19 fold for the N747A mutant. Residues I481, L483, K493 in 
helix D and L751, K752, L748 in helix J form contacts via van der Waal’s interactions 
(illustrated in Figure 1.8). Mutations of these residues significantly destabilize the dimer 
interface. For example in mutations I481A and L751A, responses to glutamate were not 
detected until application of cyclothiazide, indicating that these mutations severely 
compromised the dimer interface, while substitution L748A produced a mutant with 12 
fold faster desensitization kinetics. Surprisingly both mutations L483A and K752A 
produced a receptor with a slower onset of desensitization. This result would indicate that 
these residues actually produce steric hindrance within the dimer interface and their 
truncation to alanine results in a more stable dimer interface (Horning and M yer, 2004). 
Interactions observed between two dimers occur at the lateral dimer interface and are 
much less profound than those between two subunits in a dimer (Sun et al., 2002). 
Structures involved in these interactions include side chains from loop 1 in domain 1 and 
helices F, G and K in domain 2 (Figure 1.8).  
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Figure 1.8: Schematic representation of an AMPA receptor tetramer, based on a crystal 
structure of N754D mutant. Subunits A and B as well as C and D form dimers. Top view 
of the tetramer is illustrated on the top portion of the figure  and side view is illustrated 
on the bottom (from (Horning and Mayer, 2004). 
 
The amino acids that form the interaction sites are highly conserved in all AMPA 
receptors. Residues N411 and E419 of loop 1 participate in the lateral dimer interactions. 
Mutation of these residues to alanine has no effect on desensitization of the AMPA 
receptor, while deletion of the entire loop 1 produces a misfolded non-functional protein. 
Residue D668 of helix G participates in a hydrogen bond within the lateral dimer 
interface, and its mutation to alanine also has no effect on desensitization. These result  
suggest that the lateral dimer interface does not play a significant role in the mechanism 
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controlling onset of desensitization unlike the interface between subunits in a dimer that 
seems to be crucial in this mechanism (Horning and Mayer, 2004). 
The mechanism of AMPA receptor desensitization is only understood for the 
extracellular portion of the protein because the crystal structure for the complete AMPA 
receptor is unknown. It is interesting to note, however, that although the desensitized 
state is the most stable in native channels; it has never been crystallized, indicating that 
its stabilization requires portions of the protein that are absent from the crystal structure. 
Although multiple mutations on the dimer interface affected the rate of desensitization 
onset, none seemed to affect the rate of recovery from desensitization, indicating th t the 
mechanism for recovery from desensitization lies outside of the dimer interface. 
Therefore many aspects of desensitization mechanism remain unknown. 
1.4 AMPA receptor associated proteins 
AMPA receptor anchoring at the synapse involves a number of proteins that all seem 
important in retaining the ion channel at the synaptic surface (illustrated in Figure 1.9). 
Among the intracellular proteins that regulate AMPA receptor targeting and clustering 
are several proteins containing PDZ (Post synaptic density protein, Drosophila disc large 
tumor suppressor and Zonula occludens-1 protein) domains. Several lines of research 
indicate that phosphorylation of these domains at different kinase consensus sites plays a 
role in the activity-dependent synaptic plasticity and AMPA receptor internalization. 
Proteins from this family that interact with AMPA receptors include PSD-95, glutamate 
receptor-interacting protein (GRIP), protein interacting with C kinase 1 (PICK1) and 
AMPA receptor-binding protein (ABP) (Dong et al., 1997; Srivastava et al., 1998; Xia et 
al., 1999; Fukata et al., 2005; Silverman et al., 2007).  
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Figure 1.9: A schematic of AMPA receptor scaffolding at the post-synaptic membrane 
(Collingridge et al., 2004) 
 
GluR2 AMPA receptor subunit C-terminal peptide was shown to interact and 
colocalize with an ATPase N-ethylmaleimide-sensitive fusion protein (NSF) and alpha- 
and beta-soluble NSF attachment proteins (SNAPs) (A. Nishimune et al., 1998; P. Osten 
et al., 1998). NSF specifically interacts with GluR2 and GluR4c, but not any other 
AMPA receptor subunits, demonstrating that this interaction can mediate an important 
step in trafficking of AMPA receptors with specific composition (Song et al., 1998). 
1.4.1 AMPA receptor auxiliary subunits – transmembrane AMPA receptor regulatory 
proteins (TARPs). 
A spontaneous mutation in a mouse that presented with ataxic gait, upward head-
elevating movements and episodes of epileptic spike-wave discharges identifie at 
Jackson Laboratories revolutionized the AMPA receptor field (Letts et al., 1998). The 
mouse was named stargazer and the protein responsible for the phenotype was named 
stargazin, also referred to as γ2 by homology with the voltage gated calcium channel γ1 
subunit (Letts, 2005). Several other γ subunits were subsequently cloned and now include 
γ 1 - γ 8 (Klugbauer et al., 2000; Burgess et al., 2001; Moss et al., 2002). Because the 
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stargazer mutation altered calcium entry in neurons and thus caused the seizure 
phenotype, it was originally thought that stargazin mediated its effect via modulati n of 
calcium channels (Letts et al., 1998). Further studies determined that stargazin was 
predominantly expressed in cerebellar granule cells and the stargazer phenotype was 
caused by the lack of functional AMPA receptors. This finding implicated stargazin’s 
role in normal AMPA receptor function instead of voltage gated calcium channels, as 
previously thought (Chen et al., 2000). 
The first set of studies concentrated on the function of stargazin in synaptic targeting 
of AMPA receptors. Stargazin has a C-terminal PDZ-binding domain, essential for 
binding to post synaptic density 95 (PSD-95) and PDZ domain-containing proteins 
SAP97, SAP102 and nPIST: property crucial for delivery of AMPA receptors to synapses 
and anchoring them in place (Chen et al., 2000; Ives et al., 2004). This mechanism of 
delivery is regulated via PKA phosphorylation at Thr321 in the C-terminal tail of 
stargazin. As the site becomes increasingly phosphorylated the association of stargazin 
with PSD-95 is decreased dramatically, thus regulating the number of AMPA receptor – 
stargazin complexes in the post-synaptic membrane (Chetkovich et al., 2002; Choi et al., 
2002). Interaction of stargazin with PSD-95 is believed to control the number of AMPA 
receptors in the post-synaptic membrane (Schnell et al., 2002).  
Wide distribution of AMPA receptors in the brain led to a hypothesis that proteins 
homologous to stargazin might be expressed throughout the brain and may influence 
AMPA receptor function. Homology cloning identified total of eight γ subunits γ1- γ8, 
which possess four trans-membrane domains with both N- and C-termini on the 
intracellular side of the cell and are homologous to the claudin family of proteins and cell 
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adhesion molecules essential in forming epithelial tight junctions (Morita et al., 1999). 
Stargazin (γ2) related proteins, that include γ3, γ4 and γ8, have been grouped into Class I 
transmembrane AMPA receptor regulatory (TARP) subunits based on homology and 
their effects on function of all AMPA receptors, while closely related γ5 and γ7 are 
classified as Class II TARPs and are specific to GluR2 (Tomita et al., 2005a; Turetsky et 
al., 2005; Kato et al., 2007; Korber et al., 2007; Kato et al., 2008). γ1 and γ6 have been 
shown to associate with and have effects on voltage-gated calcium channels (VGCC) 
(Arikkath et al., 2003). Figure 1.10 represents a phylogenic tree showing a relationship 
between γ subunits and related proteins (taken from Tomita 2003). 
 
Figure 1.10: Schematic representation of the phylogenetic relationship between diffrent 
γ subunits and their related proteins (from Tomita 2003). 
 
All of the proteins in the γ subunit family have a conserved consensus site for C-
linked mannosylation (GLWXXR). It is currently unknown if this site is mannosylated in 
any of the γ subunits, the only confirmed mannosylation was present in one of the 
distantly related tetraspanin proteins - membrane protein 20 (MP20) and played a rol  in 
the export of the protein from the ER and its association with other proteins (Ervin et al., 
2005). Although most of the γ subunits carry a consensus sites for N-linked glycosylation 
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(NXTX), the role of this glycosylation in the function of the protein remains unknown. 
To date only γ1 has been definitively shown to be glycosylated and removal of this 
glycosylation did not affect association with VGCC (Arikkath et al., 2003).  
Effects of all TARPs on glutamate receptor family are exclusive to AMP  receptors 
(Chen et al., 2003). TARPS are physically associated with the majority of AMPA 
receptors in the brain, leading to the conclusion that they are AMPA receptor’s auxiliary 
subunits (Vandenberghe et al., 2005a, b). This physical association of AMPA receptors 
with TARPs plays a role in receptor trafficking, where TARPs behave as ER chaperones, 
ensuring the correct folding and delivery of the protein to the membrane (Vandenberghe 
et al., 2005b). The C-terminus of stargazin contains a conserved motif that that binds to 
PDZ domains of post-synaptic proteins such as PSD-95, thus stabilizing AMPA receptors 
at the membrane (Chen et al., 2000). In addition to trafficking and anchoring functions, 
TARPs play a role in positive allosteric modulation of AMPA receptor function by 
reducing receptor desensitization in response to glutamate, slowing recepto deactivation, 
potentiating kainate responses, attenuating internal polyamine block and increasi g 
receptor trafficking and rate of channel opening (Priel et al., 2005; Tomita et al., 2005b; 
Turetsky et al., 2005; Soto et al., 2007). Homomeric and heteromeric AMPA receptors 
expressed in heterologous expression systems have a weak non-desensitizing respo se to 
kainate. However when co-expressed with TARPs the responses are potentiated 200-fol
(Turetsky et al., 2005).The effect of stargazin on the responses to kainate is mediated by 
an effect distinct from its effect on glutamate desensitization (Turetsky t al., 2005). 
Different domains of stargazin have been implicated in above modulatory functions of 
the AMPA receptor (Figure 1.11).  
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Figure 1.11. Both intracellular and extracellular regions of γ2 mediate functional changes 
in AMPA receptor properties. A, Schematic depiction of the transmembrane topology of 
γ2. Amino acids demarcating boundaries for the chimeras and the C-terminal truncations 
are noted. Current density (B), normalized glutamate steady-state currents (C), and 
normalized kainate currents (D) in HEK293 cells transfected with GluR1 alone or GluR1 
plus γ2, γ2( 26-103)/ γ5(ins26-99), γ2( 89-103)/ γ5(ins85-99), γ2(1-212), γ2(1-244), or 
γ2(1-288) are shown. The error bars in B-D represent the mean ± SEM (n = 9-46). *p < 
0.05, ** p < 0.01, *** p < 0.001, significant difference relative to the corresponding control; 
+p < 0.05, ++p < 0.01, +++p < 0.001, significant difference from γ2 condition. Glu, 
Glutamate; Con, control; KA, kainate; SS, steady state; Pk, peak. Figure taken from 
(Turetsky et al., 2005). 
 
Chimeric exchanges of the first two-thirds of stargazin’s extracellular oop Ex(26-
103) generated a protein with decreased effects on AMPA receptor desensitization, 
kainate efficacy and slightly but significantly decreased trafficking. While the smaller 
exchange Ex(89-103) presented with only a slight decrease in kainate efficacy, indi ating 
that most of the stargazin’s function on AMPA receptor desensitization and kainate 
efficacy is located in the first two-thirds of the first extracellular loop. The largest 
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truncation of the C-terminal tail γ2(1-212) of stargazin presented with complete loss of 
trafficking and decreased effects on AMPA receptor desensitization and kainate efficacy 
(Figure 1.11). While the smaller truncations γ2(1-244) and γ2(1-288) presented with 
gradual increases in trafficking and kainate efficacy, suggesting that the entire C-terminal 
tail of stargazin is important for trafficking and kainate efficacy. In summary, the first 
extracellular loop of stargazin is involved in modulating AMPA receptor desensitization, 
kainate efficacy and trafficking, while the intracellular C-terminal tail of stargazin mostly 
modulates trafficking (Turetsky et al., 2005). The C-terminal cytoplasmic tail of stargazin 
also has a signal sequence that promotes sorting and trafficking of AMPA receptor to the 
cell surface (Bedoukian et al., 2008). Recent studies indicate that the  intracellular N-
terminus and loop of stargazin may also contribute to AMPA receptor gating (Milstein 
and Nicoll, 2009) 
Association of AMPA receptor with TARPs alters receptor pharmacological 
properties in response to positive modulators, competitive and non-competitive 
antagonists (Cokic and Stein, 2008; Soto et al., 2009). For example, the AMPA receptor 
positive modulator cyclothiazide displays a preference for flip ather than flop isoforms of 
the receptor. Co-expression of AMPA receptor with TARPs attenuates this preference, 
making both splice variants almost equally sensitive to cyclothiazide (Tomita et al., 
2006). TARPs also modulate the ligand efficacy of AMPA receptors. In the absence of 
TARPs, quinoxalinedione compounds such as 6-cyano-7-nitroquinoxaline-2,3-dione 
(CNQX) are AMPA receptor antagonists. A crystal structure of GluR2 with CNQX 
bound reveals that CNQX induces a slight domain closure (<1 degree), a movement that 
is not enough to open the ion channel. However, when AMPA receptors are co-expressed 
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with TARPs, CNQX becomes a partial agonist. This result may indicate that TARPs act 
by strengthening a coupling mechanism between the ligand-binding core and the ion pore 
(Menuz et al., 2007). Co-expression of stargazin also increases efficacy and app rent 
affinity of the AMPA receptor to non-competitive antagonists GYKI 52466 and GYKI 
53655, shifting the dose inhibition response curve to the left (Cokic and Stein, 2008). 
Taken together, these studies emphasize the significance of TARPs as AMPA receptor 
auxiliary subunits. It is now widely accepted that TARPs are crucial components of 
neuronal AMPA receptors and different TARP isoforms are important determinants of 
the properties of excitatory post-synaptic potentials (EPSPs) of various synapses (Fukata 
et al., 2005; Tomita et al., 2005a; Turetsky et al., 2005; Cho et al., 2007). Their co-
expression in the brain plays an important functional role in the development and wiring 
of the nervous system (Dakoji et al., 2003; Tomita et al., 2005b; Deng et al., 2006). 
1.4.2 Auxiliary Subunit - Cornichon 
Recent studies using proteomic analysis of native AMPA receptor complexes 
identified cornichon homolog 2 (CNIH-2) and cornichon homolog 3 (CNIH-3) to be 
specifically associated with AMPA receptors (Schwenk et al., 2009). Cornichon proteins 
are only present in AMPA receptor complexes without TARPs. CNIH-2 and CNIH-3 
have topology distinct from TARPs with an intracellular N-terminus, 3 transmembrane 
domains and extracellular C-terminus.  Previous experimental evidence has shown their 
involvement in polarization of the embryo in Drosophila and ER protein export in yeast 
(Bokel et al., 2006; Castillon et al., 2009). Consistent with their role in trafficking 
cornichon proteins increased surface expression of homomeric GluR1flop 10-fold in a 
Xenopus Oocyte expression system. In addition to trafficking, cornichons also appear to 
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modulate AMPA receptor channel gating. Based on these observations, cornichon 
proteins are now considered, along with TARPs, as AMPA receptor auxiliary subunits 
(Schwenk et al., 2009).   
1.5 Significance 
AMPA receptors have been implicated in the synaptic changes underlying animal 
models of learning and memory, including long-term potentiation (LTP) (Anderson and 
Lomo, 1966; Shi et al., 1999) and long-term depression (LTD) (Barrionuevo et al., 1980; 
Christofi et al., 1993). In both cases, the synaptic changes that occur in response to 
stimuli result in  an increase (LTP) or decrease (LTD) of the number of AMPA receptors 
at the synapse (Shi et al., 1999). In addition to regulation of AMPA receptor number, 
pore-forming subunit composition of AMPA receptors (Zhu et al., 2000), including the 
addition of different auxiliary subunits (Fukaya et al., 2006; Bats et al., 2007), has also 
been implicated in synaptic plasticity. These processes have also been implicated not 
only in memory formation but also normal development of the brain (Kirkwood et al., 
1995) and involve different mechanisms at different stages of organism development 
(Yasuda et al., 2003). 
Western society has long been plagued by increased incidence of cardiovascular 
disease. According to the American Heart Association, one in every four Americans will 
develop cardiovascular disease, accounting for 40% of all death in the USA. With 
development of modern medicine, the survival rate during heart attacks has increased 
dramatically. However, patients surviving these episodes can be left with insurmountable 
cognitive and motor disabilities caused by exitotoxic events in the CNS. During ischemic 
conditions in the brain following a heart attack or a stroke, production of neuronal ATP is 
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decreased, leading to elevated vesicular release of glutamate and impaired u take of the 
neurotransmitter. This abnormal glutamate release and uptake contribute to the over-
excitation of post-synaptic neurons: activation of AMPA receptors that leads to 
membrane depolarization and increased calcium influx through NMDA receptors. 
Elevated intracellular calcium causes a series of events that lead to cell death, termed 
excitotoxicity (Choi, 1988). In vivo evidence from animal models indicates that use of 
AMPA receptor competitive antagonists during ischemic events reduces the size of
ischemic lesions (Sheardown et al., 1990), while use of AMPA receptor non-competitive 
antagonists may be protective against AMPA receptor mediated excitotoxicity (May and 
Robison, 1993). Such therapies in human patients suffering from strokes and heart attacks 
could be used to minimize neuronal damage in the CNS, thus increasing the quality of 
life for survivors.  
AMPA receptors are thought to mediate neuronal damage in amyotrophic lateral 
sclerosis (ALS) and epilepsy (Pollard et al., 1993). Deficits in synaptic transmission 
underlie the dementia in Alzheimer’s disease, and blocking AMPA receptor 
desensitization may be beneficial in treatment of dementia symptoms. In models of 
inflammatory and neuropathic pain, up-regulation of glutamate receptors contributes to 
nociceptive behaviors (Carlton and Coggeshall, 1999). Thus, blocking glutamate 
receptors has anti-nociceptive effects (Hunter and Singh, 1994). 
ALS is caused by degeneration of motor neurons and in 10% of the cases it is caused 
by sporadic mutations in superoxide dismutase 1 (SOD1) (Rosen et al., 1993). Motor 
neuron degeneration in the other 90% of the case remains unclear and three differentnon-
exclusive mechanisms are supported by experimental evidence. The first suggess that 
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over activation of calcium permeable glutamate receptors in response to increased release 
of glutamate contribute to this degeneration (Yin et al., 1995). The second one proposes 
that motor neurons are selectively vulnerable to excitotoxic events because of their high 
density of AMPA receptors (Vandenberghe et al., 2000). The third one relies on the fact 
that some of the ALS patients carry mutations in the glutamate transporter GLT-1, 
suggesting that pathogenesis of ALS is in part a result of decreased glutamate re-uptake 
and the resulting prolonged activation of AMPA (Meyer et al., 1995; Rothstein et al., 
1995). 
Epilepsy is a common disorder, resulting in synchronous activity in the brain, 
affecting approximately 50 million people worldwide. There are multiple causes of 
epilepsy, approximately 10% are caused by mutations in voltage-gated or ligand-gated 
ion channels (Yamakawa et al., 1995; Wallace et al., 1998; Catterall et al., 2008). In some 
cases, mutations of a voltage-gated sodium channel result in a longer channel open time 
and prolonged glutamate release from the pre-synaptic terminal. AMPA receptors have 
been shown to play a role in the cell death after seizures and increased influx of calcium
through calcium permeable glutamate receptors has also been shown to contribute to this 
process (Pollard et al., 1993).  
In Alzheimer’s disease, amyloid beta peptides are accumulated in the matrix 
surrounding neurons causing dementia. The recent literature indicates that synaptic 
AMPA receptors are down regulated in the early stages of the disease (Armstrong et al., 
1994) and that the cognitive defects observed in the process of the disease are actually a 
result of synaptic failure, not neuronal cell death (Selkoe, 2002). Therefore use of 
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nootropic drugs, like aniracetam or AMPAkines, that reduce AMPA receptor 
desensitization may help reduce the rate of synaptic failures. 
With increasing knowledge of the role of AMPA receptors in the above disorders, 
more treatment options can be developed and ultimately more lives can be saved or 
dysfunction ameliorated. Understanding AMPA receptor desensitization better might 
provide insight into rational drug design for pore-forming subunits. Also, because 
TARPS have such a profound effect on AMPA receptor desensitization and 
pharmacology, they may provide a new target for rational drug design. The medical as 
well as scientific field could benefit greatly from the research unlocking mysteries 




RESEARCH DESIGN AND METHODS 
2.1 Site directed mutagenesis 
In order to prepare constructs utilized in this project, mutations were introduced into 
the GluR1 AMPA receptor protein (AMPA receptor clones were a gift from Dr. P. H. 
Seeburg; Max Planck Institute for Medical Research, Heidelberg, Germany) as well as 
TARPS γ2 (cloned from adult rat cerebellum) and γ5 (cloned from adult rat forebrain), 
using the ProSTAR Ultra HF RT-PCR system (Stratagene, La Jolla, CA). The 
QuickChange II XL site-directed mutagenesis kit from Stratagene is optimized for site-
directed mutagenesis of double-stranded plasmids with large inserts (the plasmid is 10 kb 
and GluR1 is 5 kb).  This kit utilizes thermal cycling to denature the parental DNA 
template, anneal the primers introducing the mutations and extend the primers with 
PfuUltra DNA polymerase. Digestion of the parental DNA plasmid with DpnI 
endonuclease follows thermal cycling (DpnI Endonuclease is specific for methylated and 
hemimethylated DNA, therefore it will only digest the parental strands). DNA was 
transformed into XL10-Gold ultracompetent bacterial cells and individual colonies were 
selected after plating on agar containing antibiotic. To insure that no collateral mutations 
were introduced during mutagenesis, mini-prepped DNA was sequenced at the 
Recombinant DNA/Protein resource facility at Oklahoma State University, Stillwater, 
OK. We sequenced both strands of the plasmid DNA in opposite directions and the 
sequence normally runs approximately 1200 base pairs. The total length of GluR1 is
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approximately 2700 base pairs, and because the sequence overlaps from the beginning of 
S1 to the end of S1 we usually sequence approximately 75% of the receptor. The ligand-
binding domain and transmembrane domains forming the channel are always present in 
our sequence. DNA is then maxi-prepped using a Qiagen kit and stored at 4oC. All 
mutations are done in collaboration with Dr. Turetsky’s laboratory.  
2.2 HEK293 tissue culture 
For expression of recombinant AMPA receptors, human embryonic kidney cells 
(HEK293) cells from American Type Culture Collection (Manassas, VA) were grown at 
37 degrees C in a humidified 5% CO2 incubator. 90% MEM plus Earle’s salt (Invitrogen) 
and 10% Fetal bovine serum (FBS) (Invitrogen) was used as medium for cell culture. 
Cells were passaged in 252cm flasks. Once they reached 70% confluency they were 
plated on 35 mm dishes for transfection and/or passaged. Cells were typically used up to 
passages 15-17 before being discarded. 
2.3 Transient transfections 
Because the surface of the plastic and the surface of the cells are negatively charged, 
35 mm dishes were coated with Poly-D Lysine (PDL) that is positively charged to nsure 
proper attachment of HEK293 cells. After the cells growing in the flasks reached 70% 
confluency, we plated them on the coated 35 mm dishes at 2000 cells per dish. 24 hours 
later, cells were transfected using Lipofectamine reagent from Invitrogen. For each 35 
mm dish to be transfected, 2 µg of Qiagen purified DNA was diluted in 100 µl of OPTI 
MEM (Invitrogen) and was combined with 8 µl of Lipofectamine reagent diluted in 100 
µl of OPTI MEM (use of OPTI MEM is recommended by Invitrogen for transient 
transfections). This mixture was incubated for 20 minutes at room temperature. 800 µl of 
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OPTI MEM was added to the transfection mixture to bring transfection volume to 1 ml. 
Cells were washed 3 times with 3 ml of OPTI MEM to remove all traces of serum, since 
serum interferes with transfection. The last wash was replaced with transfection solution. 
Cells were returned to the incubator for 3 hours. Following incubation, cells were wash d 
3 times with 3 ml of MEM to remove traces of DNA and lipofectamine, and were fed 
with complete culture medium supplemented with 50 µM of the competitive antagonist 
NBQX (Tocris) to block activation of expressed AMPA receptors and to prevent 
excitotoxicity. Electrophysiological experiments were performed 36-40 hours later. 
DNA was transfected at a ratio of 1:1 for GluR1 and γ2. pEGFP DNA (Clontech, 
Palo Alto, CA) was included in transfection for identification of transfected cells in 
electrophysiological experiments. To avoid DNA toxicity during transfection, we always 
maintained a constant amount of DNA in each dish, 2 µg. In the past experiments in our 
laboratory we utilized heteromeric receptors as well as transfection with mul iple 
auxiliary subunits, where, for example, we used 0.55 µg of GluR1, 0.55 µg of GluR2 (or 
PSD-95), 0.55 µg of stargazin and trace amounts of pEGFP. In order to keep our older 
and newer data compatible, we continued using the same amount of DNA in this set of 
experiments, while only using homomeric GluR1 and stargazin DNA in transfection. 
Therefore for transfections presented in this dissertation, we used 0.55 µg of GluR1, 0.55 
µg of stargazin and 0.9 µg of pEGFP. 
2.4 Electrophysiology 
Whole-cell patch clamp recordings were performed at room temperature with cells 
voltage clamped at -60 mV. Recording electrodes are pulled from borosilicate glass 
(World Precision Instruments, CA) using a PE-30 puller (Sutter instruments) and fire-
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polished on a Narishege microforge. Resistance in series with the cell usually was 2-7 
MΩ and was compensated using an Axopatch 200A patch-clamp amplifier (Molecular 
Devices, Foster City, CA).  Recorded data was filtered at 1-3 kHz, sampled at 2-10 kHz 
and recorded using pClamp10 (Molecular Devices) operating on a Dell computer.  
Extracellular recording solution contained (in mM) 145 NaCl, 5.4 KCl, 1 MgCl2, 1.8 
CaCl2, 5 HEPES, 5.5 glucose and 0.01 mg/ml phenol red, osmolarity was adjusted to 
300mOsm and pH adjusted with sodium hydroxide to 7.3. During the experiment, the 
recording chamber was continually perfused by bath containing extracellular recording 
solution and 500 µM of the rapidly reversible antagonist kynurenic acid (Tocris) to 
protect cells from excitotoxicity and pre-exposure to agonists. Patch pipettes wer  filled 
with intracellular solution containing (in mM) 135 CsCl, 10 CsF, 2 MgCl2, 0.5 CaCl2, 5 
Cs4BAPTA, 10 HEPES, 2 Na2ATP (all reagents obtained from Sigma) with osmolarity 
adjusted to 295 mOsm and pH adjusted with cesium hydroxide to 7.2. Cesium was used 
instead of potassium in the intracellular solution in order to block potassium channels 
present in the HEK293 cells.  
Rapid agonist application was achieved using a glass flowpipe array (12 parallel 
barrels, each 400 µm in diameter) placed near a voltage-clamped cell. The first s t of 
experiments described in Chapter 3 utilized a pump-forced perfusion (Minipuls3; Gion 
Medical Electric, Middleton, WI) through three-way solenoid valves (Isolatch; General 
Valve, Fairfield, NJ). This system achieved solution exchange around a small cell within 
5–10 ms. The remainder of the experiments described in chapters 4, 5 and 6 used a 
gravity-fed perfusion system, with 10 ml syringes filled with solutions elevated 
approximately 6 feet above the recoding platform. Solution application was controlled 
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with Lee minisolenoid valves (World Precision Instruments, CA). The data achieved by 
these different methods of perfusion appeared comparable because the decay rates of the 
glutamate peaks were undistinguishable. Nonetheless, we only used experimentally 
matched controls with every set of experiments. For both perfusion systems, valve 
opening and closing was coordinated with flowpipe movement using the Warner 
Instruments (Hamden, CT) SF-77B fast-step Perfusion system. 
A standard protocol for examining AMPA receptor glutamate kinetics, responses to 
full and partial agonists as well as positive and negative modulators was used. The actual 
sequence of drug applications was optimized for cell survival, because repeated 
applications of TCM cause cell death. Because most of the run-down occurs in the first 
three application of agonist we initially subjected cells to three 600 ms applic tions of 3 
mM glutamate that were followed by applications of 3 mM glutamate +  30 µΜ GYKI 
52466 (negative allosteric modulator of AMPA receptors), 1.5 mM AMPA, 600 
µΜ kainate, 3 mM glutamate + 500 µΜ TCM (positive allosteric modulator of AMPA 
receptors) and glutamate again in order to calculate recovery. The very last step in the 
sequence was a 3 step protocol that subjected a cell to a 500 ms application of glutamate, 
followed by a 7 second application of TCM (500 µΜ ) plus glutamate (3 mM), followed 
by a 7 second application of glutamate (3 mM) alone. Applications of drugs were 
preceded and followed by a wash in control solution. In steps where the modulators were 
applied, the cells were first pre-treated with a modulator alone. Each agonist was applied 
twice to ensure the recorded traces were repeatable. 
Every two months, the valves were tested for optimal performance. This was done by 
using HEK293 cells transfected with a mutant GluR1 construct A518S/Y519P/ 
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S784G/A789G that had faster than normal desensitization kinetics. The valves were 
matched in 6 pairs with less than 5% difference in peak responses of A518S/Y519P/ 
S784G/A789G mutant construct in response to 3 mM glutamate applications.  
2.5 Data Analysis 
Peak and steady state currents of single representative agonist-evoked responses were 
measured using Clampfit 10 (Molecular Devices, Foster City, CA). To minimize the 
variability introduced by different cell passages, transfections and valves the data sets 
were grouped with their corresponding controls based on the date they were recorded. 
Cells that did not recover to 70% of the original glutamate peak were excluded from the 
data set. In addition to cells that did not recover, cells that had peak currents over 10 nA 
or under 50 pA were also excluded from the data set. Cells with peak currents over 10 nA 
are subject to greater current leak during voltage-clamp, while the accuracy of re ordings 
from cells with peak currents under 50 pA was affected by electrical “noise” of the setup 
(10-20 pA). 
 2.5.1  Measurement of steady-state responses and percent desensitization. 
In response to agonist binding, the AMPA receptor ion channel opens and the peak 
current can be observed on electrophysiological recording, but, as the receptor enters the 
desensitized state, the peak current rapidly decays to a steady-state level. It is currently 
unclear what precisely contributes to steady-state current, whether it is merely a 
summation of the currents flowing across the membrane as receptors cycle betwe n open 
and desensitized states, or if the current flowing through a low-conducting desensitized 
state also contributes. Mean steady-state was measured relative to baseline before agonist 
application using Clampfit10 software within a 150 – 200 ms epoch. The extent of 
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steady-state desensitization was calculated relative to maximal current in the presence of 
TCM (1- Glutamate steady-state/Glutamate + TCM Peak)*100%. Two kinetic parameters 
were also used to characterize AMPA receptor desensitization, the rate at which the 
receptor enters and recovers from desensitization. 
2.5.2  Measurement of desensitization kinetics 
The rate of desensitization onset was measured as an exponential fit of the decay from 
glutamate peak to steady-state in the continued presence of 3 mM glutamate. The 
Chebyshev function used for fitting was generated by Clampfit10 software. 
 The rate of recovery from desensitization was assessed using a 3 step protocol. 
Benzothiadiazine modulators that block AMPA receptor desensitization (cyclothiazide 
and trichlormethiazide (TCM) cannot bind AMPA receptors in the desensitized stat  (Sun 
et al., 2002). Therefore this limited binding of benzothiadiazines can be demonstrated 
electrophysiologically by its dramatically slowed association with the receptor in the 
presence of glutamate. The rate of TCM on-rate is proportional to the rate at which 
AMPA receptors recover from desensitization (illustrated in Figure 2.1). The two-
exponential Chebyshev function used for fitting the rate of recovery from desensitization 
was also generated by Clampfit10 software. The slow component of the exponential fit 
was usually the larger component and because both components decrease in constructs 
co-expressed with stargazin, the slow component was illustrated as representative. 
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Figure 2.1: Stargazin speeds binding of positive allosteric modulators. (A) Responses to 
a 3 step-protocol from hippocampal neurons transfected with GFP (above) or γ2+GFP 
(below) show the association kinetics of TCM (500 µM) in the presence of glutamate (3 
mM) (B). Onset kinetics were fit with the sum of two exponentials (% contribution of τ 
slow is shown).  Bars represent mean ± SEM (control n = 19, γ2 n = 17).  Asterisks 
indicate a significant difference between γ2 and the corresponding control (** P<0.01, 
*** P<0.001); (Turetsky et al., 2005). 
 
2.5.3  Measurement of trafficking 
The whole cell current is directly proportional to the number of AMPA receptors on 
the surface, therefore the maximal current density of AMPA receptors expressed at the 
cell surface was obtained by dividing the peak current obtained by co-application of 3 
mM glutamate and 500 µM trichlormethiazide (to block receptor desensitization) by the
whole cell capacitance (pA/pF). Although cyclothiazide is the most widely used drug to 
block AMPA receptor desensitization, we used its analog trichlormethiazide because it 
has much faster association and dissociation kinetics while having the same effect on 
blocking AMPA receptor desensitization as cyclothiazide. This functional measure of 
AMPA receptor trafficking was validated with surface biotinylation experim nts 
(Turetsky et al., 2005) 
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2.6 Statistical Analysis 
Peak and steady state currents of the single representative agonist-evoked r sponses 
were measured using Clampfit 10 (Molecular Devices, Foster City, CA). Statistics were 
preformed using a SigmaStat 3.1 software package (Systat Software Inc, 2004). For 
comparison of two groups, unpaired Student’s T-test was used. For comparison of 
multiple groups, the data was evaluated using a One-Way ANOVA with Student-
Neuman-Keuls post-hoc tests. The level of significance was set to P<0.05 while the 
power of the performed test was above 0.8 for all analyses presented in this dissertation. 




MECHANISM UNDERLYING THE EFFECT OF STARGAZIN ON AMPA 
RECEPTOR DESENSITIZATION 
3.1 Introduction 
In response to agonist binding the AMPA receptor ion channel opens and the peak 
current can be observed in electrophysiological recording, but, as the receptor enters the 
desensitized state, the peak current rapidly decays to a steady-state level. Co-expression 
of AMPA receptors with TARPs results in a desensitization profile that dramatically 
differs from that of pore-forming subunits expressed alone. TARPs modulate AMPA 
receptor functional properties by decreasing the amount of steady-state desensitization 
(Turetsky et al., 2005), increasing the efficacy of the agonist and slowing the rate of 
channel deactivation (Priel et al., 2005). Three plausible mechanisms have been proposed 
to explain stargazin’s effect on AMPA receptor steady-state desensitization.  
The first mechanism, proposed by Priel and colleagues, suggested stargazin acts to 
stabilize the dimer interface, and thus slows the onset of desensitization. They found that 
stargazin changes the EC50 of glutamate in homomeric GluR3 receptors (from 18.5 ± 0.5 
µM without stargazin to 5.0 ± 0.3 µM with stargazin), while being unable to do so in the 
L507Y mutant construct, which already exhibits increased agonist efficacy (from 18.5 ± 
0.5 µM in GluR3 to 4.3 ± 0.1 µM in L507Y). The authors assumed that the effects of 
stargazin on AMPA receptor agonist efficacy, deactivation and desensitization are caused 
by the same mechanism and, because effects of stargazin were occluded by the L507Y 
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mutation, that stargazin must act by the same mechanism as the L507Y mutation, i.e. by 
stabilizing the dimer interface (Priel et al., 2005). However, because the experiments 
were done in the Xenopus Oocyte expression system, where rapid desensitization kinetics 
cannot be observed, and in the presence of positive allosteric modulator cyclothiazide, 
their data are difficult to interpret.  
The second mechanism, proposed by our laboratory, suggests that stargazin decreases 
steady-state desensitization by destabilizing the desensitized state. Benzothiadiazines like 
cyclothiazide and trichlormethiazide (TCM) cannot bind AMPA receptors in the 
desensitized state (Sun et al., 2002). This limited binding of benzothiadiazines can be 
demonstrated elecrophysiologically by its dramatically slowed association with the 
receptor in the presence of glutamate. Co-expression with TARPs speeds bindingof the 
positive allosteric modulator TCM to AMPA receptors in the presence of glutamate, thus 
suggesting that the rate of recovery from the desensitized state is increased (Turetsky et 
al., 2005).  
The third proposed mechanism relies on single channel evidence indicating that co-
expression with stargazin increases relative frequency of large conductace openings and 
causes a two-fold increase in duration of bursts without an actual change in the leng  of 
individual openings. Zhang et al. suggest that the effects of stargazin on desensitization 
are secondary to its effects on gating kinetics (Zhang et al., 2006). Although, the effects
of stargazin on gating kinetics in neurons are apparent, they are not mutually exclusiv  
with stargazin’s effect on the rate of recovery from desensitization.  
To elucidate the mechanism of TARP modulatory action on AMPA receptor 
desensitization, we utilized the effects of mutations known to affect protein in ractions 
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in the dimer interface (helices D and J) and examined the effects of γ2 on desensitization 
kinetics in these mutants. Figure 3.1 illustrates the crystal structure of th GluR2 dimer 




the GluR2 flop 
crystal structure. 
Left: side view of 
the intra dimer 
interface; Right: 
top-down view of 




In GluR2 residues L483 (in helix D) and K752 (in helix J) introduce steric hindrance 
within the network of bonds that stabilize the dimer interface. Removing the steric 
hindrance by truncating these residues to alanines results in a more stable dimer interface 
and thus slower onset of desensitization (Horning and Mayer, 2004), while mutating 
L483 to tyrosine creates an additional salt bridge between adjacent subunits and 
completely blocks desensitization (Stern-Bach et al., 1998; Sun et al., 2002). Residues 
E486 and K493 (in helix D) and N747 and E755 (in helix J) participate in a network of 
hydrogen bonds supporting stability of the dimer interface connecting helix D of one
subunit with helix J of another. Truncation of any of these residues to alanine results in a 
less stable dimer interface and increased rate of desensitization onset. Inter stingly, none 
of the mutations on the dimer interface had an affect on AMPA receptor recovery from 
desensitization (Horning and Mayer, 2004).  
Although most of the crystallographic work has been done in the GluR2 subunit, 
homomeric GluR2 receptors do not occur endogenously and are difficult to work with in 
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electrophysiological experiments due to their low conductance. In contrast homomeric 
GluR1flip subunits produce robust responses and are endogenously expressed. Thus we 
made some of the corresponding mutations in GluR1. Table 3.1 lists mutations that had 
intermediate desensitization phenotypes and were chosen for the electrophysiolgical 
experiments outlined below.  
Table 3.1: Residues on the AMPA receptor intra-dimer interface having an 







partner Location  
Effect on 
Desensitization 
Rate in GluR2 
Reference 
L483Y* L479Y L748, L751 helix D 
prevents 
desensitization 
(Stern-Bach et al., 
1998) * 







helix D 46-fold increase 
(Horning and 
Mayer, 2004) 
N747D N743D E486 helix J 19-fold increase 
(Horning and 
Mayer, 2004) 
K752A K748A helix D helix J 4.7-fold decrease 
(Horning and 
Mayer, 2004) 
* L507Y mutation was originally done in GluR3 
3.2 Statement of hypothesis 
Because stargazin modulates AMPA receptor desensitization by controlling the rate 
of recovery from desensitization, stargazin’s effects should be additive wih constructs 
carrying mutations of the residues on the dimer interface controlling the rate of 
desensitization onset. 
3.3 Results and Discussion 
To elucidate the mechanism responsible for the effect of TARPs on AMPA receptor 
desensitization, mutations listed in Table 3.1 were made in a GluR1 background and 
expressed as homomers with and without stargazin. Whole cell patch clamp recordings 
were performed to identify the effects of these mutations on AMPA receptor.  
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First we assayed the effects of the mutations on AMPA receptor expression. All f 
the constructs produced robust currents, indicating that mutated constructs were 
processed by the ER machinery and expressed as functional proteins on the plasma 
membrane (in fact the L479A construct had significantly higher current density when 
compared to a control). Although, in all cases, the mutated GluR1 constructs co-
expressed with stargazin showed significantly increased trafficking, the fold effect of 
stargazin on trafficking of different constructs was not the same (Figure 3.2) 
 
Figure 3.2: Stargazin increases trafficking of mutations that participate in the stability of 
the intra-dimer interface. As a functional measure of trafficking, peak currents for 
glutamate + TCM application were divided by whole cell capacitance to yield current 
density (pA/pF). Bar graphs represent means ± SEM, n=9-18. * indicates statistical 
difference within a construct, # indicates statistical significance as compared to GluR1, $ 
indicates significance as compared to GluR1γ2. (* P<0.05; ** P<0.01; ***P<0.001) 
 
3.3.1 The effects of stargazin and mutations stabilizing the intra-dimer interface on 
AMPA receptor desensitization. 
In our attempt to elucidate the mechanism of stargazin’s action on AMPA receptor 
desensitization, we examined desensitization properties of mutants listed in Table 3. The 
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decay of the glutamate peak was fit with exponential function to determine the rate of 
desensitization onset for these constructs. Because the rate of desensitizatio  onset and 
the degree of steady-state desensitization are not necessarily correlated for all dimer 
interface mutants, (Horning and Mayer, 2004) we also characterized percent 
desensitization relative to maximal current in the presence of Glutamate + TCM (% 
desensitization = (1-Glutamate Steady-State / Glutamate + TCM Peak)*100%). 
Because previous results from the Xenopus Oocyte expression system suggested that 
stargazin’s functional effects on L507Y mutant were occluded by the mutation, we 
transferred this mutation to a GluR1 background (L479Y) and examined its 
desensitization properties in HEK 293 cells. In agreement with Priel et. al., our data 
indicate that the only effect of stargazin in this mutant is increased trafficking (Figure 
3.3).  
 
Figure 3.3: Co-expression of L479Y mutant with stargazin does not further decrease 
AMPA receptor desensitization. Representative traces of responces to glutamate and 
glutamate + TCM in GluR1 (A) and L479Y (B) expressed with (lavender) and without 
(black) stargazin. Black solid line indicates the duration of glutamate application, while 
the open box indicates the duration of TCM application. The scale bars indicate whole-
cell current amplitude and time in milliseconds. Percent desensitization of glutamate 
traces (C). Bar graph represent means ± SEM, n = 9-12. * indicates statistical difference 
within a construct, # indicates statistical significance as compared to GluR1, $ indicates 




However, because mutation of residue L479 to tyrosine essentially locks the dimer 
interface by introducing a salt bridge, it prevents the receptor from ever entering the 
desensitized state. Thus this mutation is not useful in elucidating the mechanism of 
stargazin’s action on AMPA receptor desensitization. 
We next examined the previously described L479A, a mutation with a less severe 
desensitization phenotype. Interestingly, unlike in GluR2, this mutation in GluR1 was 
indistinguishable from control (Figure 3.4 C, I, J, and K). Such discrepancy is probably 
caused by the innate differences between GluR1 and GluR2 subunits. 
Mutation of K748 to alanine resulted in a construct that behaved similarly to its 
GluR2 counterpart. Steady-state desensitization of K748A was significantly reduced and 
the rate of desensitization onset was significantly slower when compared to control 
GluR1, indicating that mutation of this residue stabilized the dimer interface (Figure 3.4 I 
and J). 
Mutation E482A was previously shown to cause an increase in the rate of 
desensitization onset in GluR2 (Horning and Mayer, 2004). However, when we examined 
this mutation in GluR1, it had an opposite effect on desensitization properties. This 
construct had a significantly slowed rate of desensitization onset and decreased steady-
state desensitization (Figure 3.4 I and J). This inconsistency probably also arose from 
differences between the GluR1 and GluR2 protein structure.  
In agreement with Horning et. al., we did not observe changes in the kinetics of 
recovery from desensitization in any of the above described mutations, indicating th t 
their main effect was on the onset of desensitization (Figure 3.4K). 
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Figure 3.4: Effects of stargazin on desensitization in mutations that stabilize the dimer 
interface are additive. Representative traces for glutamate in the presence and absence of 
TCM for GluR1 (A), L479A (C), E482A (E) and K748A (G) expressed with (lavender) 
and without (black) stargazin. Traces to a 3 step protocol demonstrate relative recovery 
from desensitization of GluR1 (B), L479A (D), E482A (F) and K748A (H) expressed 
alone (black) or with stargazin (lavender). Percent desensitization is measured relative to 
glutamate + TCM peak (I). The time constant of desensitization onset was determin d by 
fitting a decay of glutamate peak with a single exponential function (J). The time constant 
of recovery from desensitization is represented by the slow component of a two 
exponential fit of the TCM on-rate in the presence of glutamate (K). Bar graphs represent 
means ± SEM, n = 9-18. * indicates statistical difference within a construct, # indicates 
statistical significance as compared to GluR1, $ indicates significance as ompared to 
GluR1γ2. (* P<0.05; ** P<0.01; ***P<0.001). 
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Interestingly, the mutations on helix D, L479A and E482A, had an unexpected effect on 
negative cooperativity between glutamate and trichlormethiazide as shown in the traces 
of these constructs (Figure 3.4 C and E). As more glutamate binds the ability of TCM to 
block desensitization in these mutants was reduced. Because part of the binding site for 
TCM is located on the dimer interface and is coordinated by the residues on the β strand 
7, downstream of helix D, it is possible that the mutations of the residues in helix D alter 
the conformation or exert tension on the β strand 7 during glutamate binding, thus 
decreasing the affinity for TCM. 
To determine whether the desensitization effects of the mutations that stabilize the 
dimer interface are additive or occlude the effects of stargazin, all mutant receptors were 
expressed with γ2 and their desensitization profiles were examined. If stargazin were to 
act by stabilizing protein interactions of the dimer interface, then the effects of stargazin 
on mutations that do the same should be occluded. However if stargazin acts by making 
the desensitized state less favorable, then the effects of stargazin should be additiv  with 
the effects produced by mutations stabilizing the dimer interface.  
Steady-state desensitization of all three mutant constructs illustrated in Figure 3.4 was 
significantly reduced when expressed with stargazin (Figure 3.4 I). The rate of recovery 
from desensitization was also significantly faster in all mutations as well as control 
GluR1 (Figure 3.4 K). This result is consistent with our previous data, indicating that 
stargazin speeds the binding of positive allosteric modulators in the presence of glutamate 
(Turetsky et al., 2005). Thus, stargazin’s effects on steady-state desensitization and rate 
of recovery from desensitization in mutations that stabilize the dimer interface were at 
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least additive and possibly synergistic (compare % desensitization for E482A and K748A
relative to control GluR1). 
3.3.2 Stargazin’s effects on steady-state desensitization in a mutant constru t 
destabilizing the intra-dimer interface are occluded. 
We next examined the effects of a mutation that destabilizes the dimer interface, 
N743D. Peak responses to glutamate in this mutation were very small, suggesting that he 
receptor entered the desensitized state before the channel could open or the desensitized 
state was favored at rest (Figure 3.5 C).  
 
Figure 3.5: Effects of stargazin on steady-state desensitization in a mutation that 
destabilizes the dimer interface are occluded. Representative traces for glutamate in the 
presence and absence of TCM for GluR1 (A), N743D (C) expressed with (lavender) and 
without (black) stargazin. Traces to a 3 step protocol demonstrating the recovery fr m 
desensitization of GluR1 (B), N743D (D), expressed alone (black) or with stargazin 
(lavender). Percent desensitization is measured relative to glutamate + TCM peak (E). 
The time constant of desensitization onset was determined by fitting a decay of glutamate 
peak with a single exponential function (F). The time constant of recovery from 
desensitization is represented by the slow component of a two exponential fit of the TCM 
on-rate in the presence of glutamate (G). Bar graphs represent means ± SEM, n = 9-18. * 
indicates statistical difference within a construct, # indicates statistic l significance as 




Steady-state desensitization of the N743D mutant was comparable to control GluR1 
(Figure 3.5 E) while the rate of desensitization onset was significantly faster than a 
control (Figure 3.5 F). However, recovery from desensitization in the N743D mutant was 
comparable to control GluR1, supporting the evidence that mutations on the dimer 
interface affect only the onset of desensitization, but not recovery from desensitization 
(Figure 3.5 D and G). 
 To elucidate the mechanism of stargazin’s action on AMPA receptor desensitization, 
the N743D mutant was co-expressed with stargazin and its desensitization profile was 
characterized. If stargazin were to act by stabilizing protein interactions on the dimer 
interface then it would be expected that stargazin would reduce desensitization of this 
mutant. However, if stargazin were to act by a different mechanism, then it would n t be 
able to overcome the instability of the dimer interface. 
When co-expressed with stargazin, currents of N743D mutant looked very different 
from the mutations that stabilize the dimer interface. Although neither the steady-state 
desensitization of N743D nor the kinetics of desensitization onset were affected by co-
expression with stargazin (Figure 3.5 E and F), the peak response to glutamate was 
increased, suggesting that stargazin reduces the number of receptors desensitiz d at rest. 
Interestingly, stargazin had a full effect on speeding the recovery from desensitization in 
N743D mutant (Figure 3.5 D and G).  
3.4 Summary of the results 
Our exploration of the mechanism of stargazin’s action on AMPA receptor 
desensitization revealed several interesting aspects about the mechanism of stargazin’s 
effect on AMPA receptor desensitization: 
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• Stargazin’s effects on steady-state desensitization are additive and possibly 
synergistic with the mutations that participate in the stabilization of the dimr 
interface. 
• Stargazin’s effects on steady-state desensitization are occluded by the mu ation 
that destabilizes the dimer interface. 
• Stagazin’s effect on the recovery from desensitization is independent from the 
mechanism controlling desensitization onset.
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CHAPTER IV 
IDENTIFICATION OF EXTRACELLULAR AMPA RECEPTOR DOMAINS 
CRUCIAL FOR TRANSDUCING EFFECTS OF STARGAZIN ON 
DESENSITIZATION AND KAINATE EFFICACY 
4.1 Introduction 
The areas of the AMPA receptor that associate with or transduce functional effects of 
TARPs have not been identified. Experiments with chimeras of γ2 and γ5 identified two 
domains important for different aspects of stargazin function: the first extrac llul r loop, 
responsible for stargazin’s effects on desensitization and kainate efficacy, and the C-
terminal cytoplasmic tail, responsible for receptor trafficking (Tomita et al., 2005a). 
Studies from our laboratory indicate that the function of these two domains is not quite so 
clear cut, with deletion of the C-terminal cytoplasmic tail also affecting desensitization 
and kainate efficacy, and changes in the first extracellular loop also impact ng trafficking 
(Turetsky et al., 2005). Our work suggests that the AMPA receptor and stargazin are 
capable of association even when most of the C-terminal cytoplasmic tail is truncated or 
when the first extracellular loop is completely exchanged with that of γ5 (Turetsky et al., 
2005), indicating that there are at least two points of association (extracellular and 
intracellular) between the AMPA receptor and stargazin, and that both of these contacts 
are necessary for full function. 
In past experiments to determine the mechanism of AMPA receptor desensitization, 
the crystal structure of the ligand-binding domain was used to identify residues that may 
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play a role in the interactions between helices on the dimer interface (Sun et al., 2002), 
while further experiments mutated these residues to elucidate and confirm the mec anism 
of AMPA receptor desensitization (Horning and Mayer, 2004). In our effort to locate the 
domains of the AMPA receptor responsible for associating with TARPs we used a similar
approach to guide our selection of residues for subsequent mutagenesis.  
Because effects of stargazin on AMPA receptor functional properties are 
predominantly associated with the first extracellular loop, we would predict that breaking 
the extracellular association would result in loss of the majority of stargazin’s effects on 
AMPA receptor desensitization and kainate efficacy, while still preserving trafficking. 
Other areas of the AMPA receptor may not directly associate with stargazin, but instead 
transduce stargazin’s effects and when mutated could also affect kainate effic cy and/or 
desensitization. Thus we would expect that a construct with almost complete loss of 
stargazin’s effect on kainate efficacy and desensitization as a candidate association point, 
while a construct with a smaller reduction in functional effects of stargazin as a  efficacy 
site.  
Figure 4.1 illustrates a top-down view of the tetrameric GluR2 ligand-binding domain 
crystal structure. The intra-dimer interface interactions, discussed in detail in Chapter III, 
are responsible for the stabilization of the interface and control the rate of desensitization 
onset (delineated by red ovals in Figure 4.1), while residues forming interactions between 
two dimers on the lateral dimer interface (delineated by green oval in Figure 4.1) did not 
affect the rate of desensitization onset (Horning and Mayer, 2004). The areas of the 
receptor that form the lateral inter-dimer interface and lateral faces of the receptor include 
loops 1 and 2 and helices B, G and K. Because of how the AMPA receptor tetramer 
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assembles, the same residues that participate in the interactions on the lateral inter-dimer 
interface are also present on the exposed lateral faces of the tetramer (delin ated by green 
brackets in Figure 4.1). The outer faces of the receptor, which include helix H, are alw ys 
exposed and are capable of interacting with other proteins (delineated by blue rack ts in 
Figure 4.1).  
 
Figure 4.1: Schematic 
representation of top-down view 
of AMPA receptor tetramer based 
on the GluR2 crystal structure. 
Red ovals indicate the location of 
the intra-dimer interface, green 
oval indicates the location of the 
lateral inter-dimer interface, 
green bracket delineates location 
of the exposed lateral face, blue 
bracket delineates location of the 
outer face of the AMPA receptor 
(Horning and Mayer, 2004). 
 
 
We assumed that residues in the AMPA receptor associating with stargazin do not 
participate in subunit interactions within the tetramer, and further that the regions of the 
receptor most likely to associate with stargazin are on the lateral and outer faces of the 
receptor. Figure 4.2 indicates the exposed residues of a single subunit. Note the location 
of loops 1 and 2 and helices B, G, K and H.  
Because stargazin does not associate with kainate receptors (Chen et al., 2003), we 
used homology to further refine areas of interest, selecting residues that were conserved 
among AMPA receptors but not between AMPA and kainate receptors. Table 4.1 lists the 
residues that fit these criteria. 
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Figure 4.2: GluR2 single subunit ligand-binding domain crystal structure. LEFT - Side 
view of the subunit, with the dimer interface pointing into the page and the outer face of 
the subunit pointing out of the page; green brackets indicate faces of possible latera  
inter-dimer interface/the lateral face of the receptor. RIGHT - Side view of the subunit, 
red bracket delineates intra-dimer interface, blue bracket indicates the outer face of the 
receptor, and possible lateral dimer interface/the lateral face of the receptor is pointing in 
and out of the page. Figure was made with the use of Chimera modeling software (UCSF) 




Table 4.1: Mutations in GluR1 receptor ligand-binding domain 
 
Construct Location N 
% Desensitization τ recovery Kainate efficacy 
alone + γ2 alone + γ2 alone + γ2 
K434T Helix B 8 99.28 99.15$$$ 4631.8### 1865.8***$$ 0.0081 0.341***$$ 
T668A Helix G 9 99.47 90.90*** 1550.2 470.2*** 0.0028 0.612*** 
K671S Helix G 9 99.25 94.81*** 2225.5 707.1*** 0.0065 0.593*** 
E674R/P675Q Helix G 9 99.11 99.25$$$ 3664.6### 3156.4$$$ 0.0209 0.297***$$$ 




of helix H 
10 99.65 99.56$$$ 3452.1### 2996.1$$$ 0.0058 0.184**$$$ 
K693G/K695D 
Downstream 
of helix H 
8 99.55 97.89$$$ 1742.8 1909.1$$$ 0.0083 0.367***$$$ 
K757M Helix K 14 99.17 93.98*** 2379.9## 705.5*** 0.0034 0.399***$$ 
D765G Helix K 14 99.74 96.83** 2699.8### 774.9*** 0.0030 0.464***$ 
GluR1  38 99.31 93.93***  1746.9 569.5***  0.0040 0.572***  
 
 
Table 4.1: Table illustrates location and phenotypes of the mutations expressed with and without stargazin in GluR1 
background. N indicates the number of cells in each data set. % Desensitization is measured as (1 – glutamate steady-state / 
glutamate +TCM peak)*100%. The rate of recovery from desensitization is represented by the slow component of a two 
exponential fit of the TCM on-rate. Kainate efficacy is measured by normalizing kainate current to Glutamate + TCM peak. # 
indicates statistical significance compares to GluR1 alone, * indicates stistical difference within each construct, $ indicates 
statistical significance compared to GluR1 co-expressed with stargazin (* P<0.05; ** P<0.01; ***P<0.001). 
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4.2 Statement of purpose 
In order to identify possible areas of association between the AMPA receptor and 
stargazin, we mutated amino acids whose side chains were pointing out of the protein and 
that were conserved among AMPA receptors, but not in kainate receptors, and examined 
them using electrophysiological techniques. 
4.3 Results and Discussion 
Because mutations in the pore-forming subunits of the AMPA receptor might affect 
receptor function on their own, mutant constructs were expressed alone and with 
stargazin and evaluated using electrophysiological methods. An initial mutation on loop 
1, N411D, was done in the GluR2Q background and did not have a different phenotype 
than control GluR2 with or without stargazin (data not shown).  
4.3.1 Mutation of residues in helix G reduce the effects of stargazin on AMPA receptor 
functional properties. 
Examination of the GluR2 crystal structure places helix G on the lower portion of the 
lateral face of the crystal. We mutated polar amino acids threonine 668 and lysine 671 
that point out and away from the helix (Figure 4.2), to corresponding GluR6 residues 
alanine (A) and serine (S), respectively. In addition, polar glutamate residue (E) in 
position 674 is located on the exposed surface of the helix and is followed by proline (P) 
675 that introduces a bend in the protein structure, thus ending helix G. Interestingly, th s 
proline residue is conserved in all AMPA receptors but not in kainate receptors, where a 
glutamine residue takes its place, indicating that the position of helix G in kainate 
receptors differs from that of AMPA receptors. Because kainate receptors do not 
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associate with stargazin, we mutated residues E674 and P675 to their corresponding 
residues in GluR6 arginine (R) and glutamine (Q), respectively, in a single construct. 
The helix G constructs were functional and trafficked robustly with the exception of 
the double mutant E674R/P675Q, which had significantly lower trafficking when 
compared to control GluR1 (Figure 4.3). When co-expressed with stargazin, all 
constructs had significantly increased trafficking, suggesting that the associ tion between 
GluR1 and stargazin responsible for trafficking was maintained. Stargazin’s effect on 
steady-state desensitization was intact with the exception of the E674R/ P675Q construct, 
where % desensitization was not affected, indicating that the functional effects o  
stargazin that control AMPA receptor desensitization were lost in this mutant (Figure 4.3 
C and F and Table 4.1). Because stargazin’s main effect on desensitization lays in the 
kinetics of the recovery from desensitization, we examined the kinetics of TCM on-rate 
in the presence of glutamate. Interestingly, the E674R/ P675Q construct expressed alone 
had a significantly slower rate of TCM on-rate in the presence of glutamate, indicating 
that the mutation affected the rate of recovery from desensitization, while T668A and 
K671S constructs had rates that were comparable to control GluR1 (Figure 4.3 D and G). 
When co-expressed with stargazin, the rates of TCM binding in the presence of glutamate 
in T668A and K671S construct were significantly decreased, indicating that stargazin’s 
effect on recovery from desensitization is intact. Intriguingly, stargazin was unable to 
decrease the rate of recovery from desensitization in the E674R/P675Q mutant construct, 
indicating that its effect on desensitization was lost (Figure 4.3 D and G). Stargazin 
significantly potentiated kainate currents in all three constructs. However, kainate  
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Figure 4.3: Residues in helix G are responsible for transducing functional effects of 
stargazin in GluR1. Representative traces for constructs alone (black) and co-expressed 
with stargazin (lavender) in response to glutamate and kainate in the presence and 
absence of TCM for GluR1 (A) and E674R/P675Q (C); and in response to a 3 step 
protocol for GluR1 (B) and E674R/P675Q (D). Summary of the results of trafficking as 
measured by whole cell currents to application of Glutamate + TCM normalized to whole 
cell capacitance (E); Percent desensitization is measured relative to glutamate + TCM 
peak (F); The time constant of recovery from desensitization is represented by the slow 
component of a two exponential fit of the TCM on-rate in the presence of glutamate (G) 
and Kainate efficacy as measured by normalizing the kainate current to Glutamate + 
TCM peak (H) are represented by bar graphs illustrating means ± SEM, n = 7-10. * 
indicates statistical difference within each constructs, # indicates statistical difference 
compared to GluR1 expressed alone, $ indicates significance as compared to GluR1γ2. (* 
P<0.05; ** P<0.01; ***P<0.001). 
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potentiation was markedly reduced in the E674R/P675Q, indicating that some of 
stargazin’s effect on kainate efficacy was also lost (Figure 4.3 C and H). 
Overall these results indicate that residues T668 and K671 in helix G are not 
important for association with, or transducing the effects of stargazin. Mutation of 
residues E674 and P675 to their corresponding GluR6 residues, however, substantially 
reduced the effects of stargazin on AMPA receptor desensitization and kainate efficacy. 
Because the mutation E674R/P675Q introduces structural changes to the protein by 
removing proline at the end of helix G, it may create tension that affects not just helix G 
but also helix H. The conservative interpretation of these results is that the mu ation 
E674R/P675Q changes the conformation of helix G and H, thus leading to loss or 
substantial weakening of association with stargazin. 
4.3.2 Residues downstream of helix H participate in association with stargazin. 
Helix H is located on the lowermost portion of the outer face of the crystal. Several 
polar lysine residues are located at the bottom of the helix and are pointing out of the 
protein, where they could interact with stargazin. 
Residue K691 on helix H (Figure 4.2) was mutated to the corresponding GluR6 
residue threonine. Interestingly, while comparing the sequence alignment of GluR1 and 
GluR6 immediately downstream of helix H, we noticed that GluR6 was missing two 
residues present in AMPA receptors, K693 and G694, while the immediately following 
residue K695 in AMPA receptors was substituted by aspartate (D) in GluR6. To resolve 
this problem two constructs were made, first with deletion of K693 and G694 plus a 
substitution of residue K695 to aspartate to mimic GluR6 spacing 
(del(K693/G694)/K695D), and second with a double mutation of K693A and K695D, 
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preserving G694 to maintain GluR1 spacing (K693A/K695D). These resulting mutations 
have different length and thus put different amounts of tension on the areas downstream 
of helix H.  
All resulting constructs were functional, however both del(K693/G694)/K695R and 
K693A/K695D trafficked significantly less than control GluR1. Stargazin, however, was 
able to significantly potentiate trafficking of all three constructs, indicating that the 
association responsible for trafficking was maintained. Although trafficking of 
del(K693/G694)/K695R and K693A/K695D co-expressed with stargazin was 
significantly reduced when compared to GluR1 co-expressed with stargazin, the 
trafficking was potentiated 2.8- and 10-fold respectively, compared to 2.5-fold for control 
GluR1 (Figure 4.4 A, C and E).  Both steady-state desensitization and the rate of recovery 
from desensitization of the K691T construct co-expressed with stargazin were 
comparable to control GluR1 co-expressed with stargazin. Co-expression with stargazin 
in del(K693/G694)/K695R and K693A/K695D constructs did not yield a decrease in 
steady-state desensitization or the rate of recovery from desensitization, indicating that 




Figure 4.4: Mutation of residues in and downstream from helix H reduces functional 
effects of stargazin in GluR1. Representative traces for constructs alone (black) and co-
expressed with stargazin (lavender) in response to glutamate and kainate in the presence 
and absence of TCM for del(K693/G694)/K695D (A) and K693A/K695D (C); in 
response to a 3 step protocol for del(K693/G694)/K695D (B) and K693A/K695D (D). 
Summary of the results of trafficking as measured by whole cell currents to application of 
Glutamate + TCM normalized to whole cell capacitance (E); Percent desensitization is 
measured relative to glutamate + TCM peak (F); The time constant of recove y from 
desensitization is represented by the slow component of a two exponential fit of the TCM 
on-rate in the presence of glutamate (G) and Kainate efficacy as measured by 
normalizing the kainate current to Glutamate + TCM peak (H) are represented by bar 
graphs illustrating means ± SEM, n = 8-10. * indicates statistical difference within each 
constructs, # indicates statistical difference compared to GluR1 expressed alon , $ 
indicates significance as compared to GluR1γ2. (* P<0.05; ** P<0.01; ***P<0.001). 
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Interestingly, del(K693/G694)/K695D mutant expressed alone had a slowed rate of TCM 
binding in the presence of glutamate, indicating that this construct was slower to recover 
from desensitization (Figure 4.4 B, and F). Stargazin was able to fully potentiate kainate 
current in the K691T construct, while being only partially effective in potentiati g 
kainate currents of del(K693/G694)/K695D and K693A/K695D (Figure 4.4 A, C and H). 
Overall these data indicate that lysine residues downstream of helix H participate in 
association with stargazin, while the exposed lysine 691 on helix H does not. Because of 
the different spacing introduced in the construct del(K693/G694)/K695D, it would be 
hard to interpret the effects caused by this mutation if taken alone. However, the rsults
with construct K693A/K695D which preserves the spacing of GluR1, indicate that these 
residues are likely an association point between the AMPA receptor and stargazin.  
4.3.3 Residues in helices K and B on the lateral dimer interface/lateral face of th
receptor are important in transducing the effect of stargazin on AMPA receptor 
function. 
Helices K and B lie on the lateral dimer interface/the lateral face of the receptor 
(illustrated in Figure 4.2). Because helix K is fully exposed and contains several polar 
residues that point out of the protein, we considered it a good candidate for association 
with stargazin. Helix B is located higher up on the lateral face of the crystal and has 
exposed residues in its upper portions. After observation of the GluR2 crystal structure, 
we selected three polar residues, K434, K757 and D765, that were pointing out of the 
protein, and were not participating in the dimer interaction and mutated them to their 
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corresponding GluR6 residues, threonine (T), methionine (M) and glycine (G), 
respectively.  
Although resulting constructs were functional, K434T and K757M trafficked 
significantly less than control GluR1. Co-expression with stargazin resulted in 
significantly increased trafficking for all three constructs, indicating that the association 
responsible for trafficking was maintained (Figure 4.5 E). In contrast to stargazin’s full 
effect on steady-state desensitization of both constructs in helix K (K757M and D765G), 
it was unable to decrease steady-state desensitization of the helix B mutant, K434T 
(Figure 4.5 F). Strikingly, while examining the rate of recovery from desensitization, we 
observed a significantly slower rate of recovery from desensitization in all three
constructs, with K434T being almost 3-fold slower than control GluR1 (Figure 4.5 G). 
Previous experiments on the intra-dimer interface elucidated the mechanism involved in 
desensitization onset, but searches there or in loop 1 and helix G failed to discover any 
residues that affected the rate of recovery from desensitization (Horning a d Mayer, 
2004). Here we show that 3 residues on the lateral dimer interface affect the rate of 
recovery from desensitization when mutated to their corresponding residues in GluR6.
When co-expressed with stargazin, the rate of recovery from desensitization w s 
significantly faster in all three constructs (Figure 4.5 G). It is of interest to note that 
although stargazin was unable to decrease steady-state desensitization of K434T, it was 
still able to significantly speed its rate of recovery from desensitization, although not to 




Figure 4.5: Mutation of residues in helices B and K reduces functional effects of 
stargazin in GluR1. Representative traces for constructs alone (black) and co-expressed 
with stargazin (lavender) in response to glutamate and kainate in the presence and 
absence of TCM for K757M (A) and D765G (C); in response to a 3 step protocol for 
K757M (B) and D765G (D). Summary of the results of trafficking as measured by whole 
cell currents to application of Glutamate + TCM normalized to whole cell capacit nce 
(E); Percent desensitization is measured relative to glutamate + TCM peak (F); The time 
constant for recovery from desensitization is represented by the slow component of a two 
exponential fit of the TCM on-rate in the presence of glutamate (G) and Kainate efficacy 
as measured by normalizing the kainate current to Glutamate + TCM peak (H) re 
represented by bar graphs illustrating means ± SEM, n = 7-10. * indicates statistical 
difference within each constructs, # indicates statistical difference compared to GluR1 




In contrast, stargazin was able to speed the recovery from desensitization to the levels of 
control GluR1 co-expressed with stargazin for the helix K mutations, indicating that it 
was able to fully rescue the desensitization deficits brought on by these mutations. 
Stargazin’s effect on kainate efficacy, however, was decreased significantly, but not 
substantially, in all three constructs, (Figure 4.5 H). 
Based on the results that stargazin was able to speed the recovery from 
desensitization in all three constructs, potentiate kainate efficacy and decreas  steady-
state desensitization in constructs in helix K, we suggest that residues in helices B and K 
do not directly associate with stargazin, but rather participate in the transduction of its 
effects on AMPA receptor function. 
4.4 Summary of the results 
In our attempt to identify areas of the AMPA receptor that associate with stargazin, 
we identified residues and helices on the exposed faces of the ligand-binding domain 
crystal that might participate in physical association with stargazin and/or transduce its 
effects on AMPA receptor function: 
• The profound nature of stargazin deficits introduced by mutation of residues 
downstream of Helix H indicates that this area is a candidate association site for 
AMPA receptor pore-forming subunit with auxiliary subunit stargazin. 
• Mutations of polar residues K434T, K757M and D765G in helices B and K on 
the lateral dimer interface/the lateral face of the receptor result in constructs 
with slowed rate of recovery from desensitization. 
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• Partial loss of effects of stargazin on mutant constructs in helices B and K 
suggest these residues participate in the transduction of stargazin’s effect  on 
AMPA receptor function. 
• Changing the conformation of the loop downstream of helix G affects the 
association with stargazin, possibly by rearrangement of residues downstream 
of helix H. 




AREAS OUTSIDE OF THE LIGAND-BINDING DOMAIN ARE IMPORTANT FOR 
RECOVERY FROM DESENSITIZATION AND STARGAZIN’S FUNCTIONAL 
EFFECTS ON THE AMPA RECEPTOR 
5.1 Introduction 
Chapter IV describes a set of experiments that focused on the identification of the 
regions in the AMPA receptor ligand-binding domain (available in crystal structure) that 
may play a role in association with TARPs. Results of these experiments idetifie  an 
area of the AMPA receptor downstream of helix H, located on the lowermost portion f 
the outer face of the crystal that could possibly interact with the stargazin molecule. In 
addition, previous work suggested that there may also be an intracellular association 
(Tomita et al., 2005a; Turetsky et al., 2005). Based on these data we suspect that there are 
additional association sites in the AMPA receptor that are located outside the crystallized 
portion of the receptor. 
While the ligand-binding domain of the AMPA receptor has been crystallized, the 
crystal structure of the majority of the receptor remains unresolved. Receptors lacking the 
N-terminal domain (in GluR1 amino acids 1-401) when co-expressed with stargazin, 
show a complete reduction in steady-state desensitization, an increase in kainate effic cy 
and an increase in receptor trafficking, indicating that this domain is not necessary for 
association with stargazin (Turetsky et al., 2005). The N-terminal domain is known to 
play a role in preferential AMPA receptor assembly (Ayalon and Stern-Bach, 2001), but 
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its other functions remain unknown. The conformation of the linker regions connecting 
the ligand-binding domain with the ion pore is also unknown. Interestingly, the M3 linker 
shares the most conservation between all AMPA and kainate receptors, while the M1 
linker and the M4 linker are conserved among AMPA receptors but differ in kainate 
receptors. Two previously described mutations in the AMPA receptor M3 linker, A636T 
(lurcher) and R624E, significantly decrease AMPA receptor desensitization (Taverna et 
al., 2000; Klein and Howe, 2004; Yelshansky et al., 2004; Schmid et al., 2007). The 
GluR1 lurcher mutation increases the affinity of the receptor for glutamate and decreas s 
steady-state desensitization (Klein and Howe, 2004), while in the R624E mutant 
construct the onset of desensitization is slowed (from 3.2 ± 0.2 msec in GluR1 to 5.8 ± 
0.3 msec in R624E) without any effect on the rate of recovery from desensitization 
(Yelshansky et al., 2004).  
The AMPA receptor C-terminal cytoplasmic tail plays an important role in r ceptor 
trafficking and its possible interactions with stargazin are the focus of work of several 
other labs (Chen et al., 2003; Tomita et al., 2004). In contrast, the intracellular loops of 
the AMPA receptor have received little attention in the research literatur  nd both their 
conformation and their role in AMPA receptor channel physiology and function remain 
unknown. Interestingly, the second intracellular loop is conserved between AMPA 
receptors and kainate receptors, with only three conservative substitutions, while the f rst 
intracellular loop differs greatly even between AMPA receptors.  
Previous research indicates that the majority of the function of stargazin on AMPA 
receptor desensitization and kainate efficacy is concentrated on the extracellular side of 
the molecule, while the majority of trafficking function is located intracellularly (Tomita 
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et al., 2005a; Turetsky et al., 2005). Recently, stargazin’s intracellular N-terminus, 
intracellular loop and C-terminus were implicated in AMPA receptor trafficking and 
gating (Milstein and Nicoll, 2009). Our results with truncations of the C-terminal 
cytoplasmic tail of stargazin suggest that losing the intracellular association not only 
diminishes receptor trafficking, but also reduces stargazin’s effect on AMPA receptor 
desensitization and kainate efficacy (See Figure 1.12). Overall these results suggest that 
multiple associations between the AMPA receptor and stargazin might exist on both 
intracellular and extracellular portions. Based on our observation with Ex(26-103) 
(Turetsky et al., 2005), we would predict that mutations on the AMPA receptor that break 
an extracellular association site would have profound loss of effect on receptor 
desensitization and kainate efficacy and mild to moderate loss of effect on trafficking (for 
details see Figure 1.10). Similarly, based on our observations deleting most of stargazin’s 
C-terminal cytoplasmic tail (delta212), we would predict that mutations on the AMPA 
receptor that break an intracellular association site would have more severe trafficking 
deficits and only moderate loss of effects on receptor desensitization and kainate effic cy. 
However, there are probably areas of the AMPA receptor outside the ligand-binding 
domain that do not directly associate with stargazin, but instead transduce its effct . 
These areas, when mutated, may also present with decreased effects of stargazin on either 
kainate efficacy or desensitization.  
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Figure 5.1: GluR1 schematic illustrating residues that were mutated and examined for 
desensitization changes. GluR1 subunit showing the ligand-binding domain, M1, M3, M4 
linkers, intracellular loops 1 and 2, C-terminal cytoplasmic tail and transmembrane 
regions. Dark blue circles indicate mutations that had no effect on desensitization, and 
red circles indicate mutations that affect GluR1 desensitization. 
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Interestingly, even though the desensitized state is the most stable in the presence of 
agonist in the endogenous receptor, this state is the hardest to crystallize, suggesting that 
regions absent from the crystal structure (linker regions, transmembrane segm nts or the 
intracellular loops) are important in stabilizing the desensitized state (M yer, 2005; 
Armstrong et al., 2006). It is, therefore, not surprising that in our attempt to locate regions 
of association between the AMPA receptor and stargazin in linker regions M1 and M4 as 
well as intracellular loops 1 and 2, we identified residues that play a role in recovery from 
desensitization. The summary of all mutations is illustrated in Figure 5.1 and presented in 
Table 5.1. 
5.2 Statement of purpose 
The purpose of the study was to identify residues in the non-crystallized portion of 
the AMPA receptor that are important for association with stargazin.  
5.3 Results and Discussion 
Mutations listed in Table 5.1 and illustrated in Figure 5.1 were made on the GluR1 
background. Residues selected for mutagenesis were conserved among AMPA receptors 
but not in kainate receptors. A number of mutations had no distinguishable 
desensitization phenotype with or without stargazin (mutations not highlighted in Table 
5.1) and they are not discussed in the data presentation below. 
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Table 5.1: Mutations outside of the AMPA receptor ligand-binding domain 
Construct Location N 
% Desensitization τ recovery Kainate efficacy 
alone + γ2 alone + γ2 alone + γ2 
K501A/K502A S1-M1 12 99.84 99.19$ 2449.3### 1250.9***$$$ 0.0011 0.359 ***$$$ 
K505G/S506T/K507N S1-M1 12 99.03 95.61** 1671.6 1091.2*** 0.0032 0.596*** 
D515N S1-M1 12 99.55 96.77** 2297.2 993.7*** 0.0046 0.558*** 
A518S/Y519P@ S1-M1 17 97.43## 77.63***$$$ 1363.6 453.5*** 0.0141# 0.691*** 
S549N IC loop 1 4 99.31 90.71** 2539.1 967.1*** 0.0026 0.599 *** 
F552P IC loop 1 6 99.28 96.82** 2584.7 599.8*** 0.0045 0.539*** 
E554N IC loop 1 6 99.71 94.29** 3077.3 576.6*** 0.0034 0.582*** 
T559V IC loop 1 6 99.36 92.65*** 1934.2 432.1*** 0.0024 0.777*** 
T560V IC loop 1 5 99.11 92.07*** 2060.7 459.9*** 0.0040 0.567*** 
S561A IC loop 1 11 99.45 96.81* 1699.4 839.6*** 0.0025 0.534*** 
S564A IC loop 1 10 99.54 97.02* 2007.1 819.9*** 0.0056 0.501*** 
S588M IC loop 2 13 99.65 97.27**$$$ 3027.8### 883.9*** 0.0036 0.359**$$ 
S591A IC loop 2 12 99.53 97.39*$$$ 1874.2## 869.6*** 0.0044 0.434***$ 
S593A IC loop 2 5 99.01 94.21*** 1876.5 498.7*** 0.0044 0.556*** 
G594T IC loop 2 13 99.73 98.58**$$$ 2806.8### 1035.9*** 0.0037 0.587*** 
R595A IC loop 2 Construct was non-functional 
K779A/D780A S2-M4 8 98.18# 92.55*** 1543.9 624.6*** 0.0141 0.675*** 
S784G/A789G@ S2-M4 8 99.69 98.82*$ 1615.1 1286.5$$$ 0.0074 0.311***$$$ 
V788I@ S2-M4 16 98.51 85.97***$$ 1478.2 522.9*** 0.0200## 0.626*** 
GluR1  38 99.31 93.93***  1746.9 569.5***  0.0040 0.572***  
@ Mutations originally reported in Balannik et al. (2005) as potential binding sites for negative allosteric modulators 
# indicates statistical significance compared to GluR1 alone, * indicates statistical difference within each construct, $ indicates 
statistical significance compared to GluR1 co-expressed with stargazin (* P<0.05; ** P<0.01; ***P<0.001). 
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5.3.1 Mutation of residues in the M1 and M4 linker regions create constructs with 
altered desensitization profiles  
Of the seven mutations in linker regions M1 and M4, three were previously identified 
by Balannik et al., (2005) as possible sites of 2,3-benzodiazepine binding (A518S/Y519P, 
S784G/A789G and V788I). These mutations met the criteria of conservation between 
AMPA receptors and were used for the experiments presented below. Our previous 
examination of the lower portion of the AMPA receptor crystal structure revealed two 
lysine residues (K501 and K502) at the very beginning of the M1 linker. Although the 
crystal structure in this area was distorted due to introduction of the artificil sequence 
connecting linkers M1 and M3, these residues appeared exposed and able to interact with 
other proteins. Therefore, we mutated them to alanines for the purpose of these 
experiments.  
All the linker constructs trafficked well (Table 5.1 and Figure 5.2 I). Three mutant 
constructs had obvious alterations in their desensitization phenotypes: K501A/K502A, 
A518S/Y519P and V788I. Mutant constructs A518S/Y519P in M1 linker and V788I in 
M4 linker had a larger steady-state and a significantly decreased percent des sitization, 
indicating that these mutations in regions immediately adjacent to the membrane had 
similar phenotypes (Figure 5.2 G and J). Interestingly, the kinetics of desensitization 
(onset and recovery) in these two mutant constructs was not affected, suggesting that he 
increased steady-state of these constructs reflects a change in channel gati g or 
conductance rather than desensitization (Figure 5.2 K, and data not shown). In support of 
this interpretation, these two mutations also significantly increased kainate efficacy, 




Figure 5.2: Mutations in the M1 and M4 linker regions affect AMPA receptor 
desensitization. Representative traces for constructs alone (black) and co-expressed with 
stargazin (lavender) in response to glutamate in the presence and absence of TCM f r
GluR1 (A), K501A/K502A (C), S784G/A789G (E) and V788I (G). Traces to a 3 step 
protocol demonstrate recovery from desensitization of GluR1 (B), K501A/K502A (D), 
S784G/A789G (F) and V788I (H) expressed alone (black) or with stargazin (lavender). 
Summary of the results of trafficking as measured by whole cell currents to application of 
Glutamate + TCM normalized to whole cell capacitance (I); Percent desensitization is 
measured relative to glutamate + TCM peak (J); The time constant of recovery fr m the 
desensitization is represented by the slow component of a two exponential fit of the TCM 
on-rate in the presence of glutamate (K) and Kainate efficacy as measured by 
normalizing the kainate current to Glutamate + TCM peak (L) are represented by bar 
graphs illustrating means ± SEM, n = 8-38. * indicates statistical difference within each 
constructs, # indicates statistical difference compared to GluR1 expressed alon , $ 
indicates significance as compared to GluR1γ2. (* P<0.05; ** P<0.01; ***P<0.001). 
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Mutation K501A/K502A had a slightly higher percent desensitization than control, 
but the result was not significantly different (Figure 5.2 C and J). However, the rate of 
recovery from desensitization in this construct was significantly slowed compared to 
control GluR1 (Figure 5.2 D and K). Interestingly, this mutation looked similar to that we 
have previously observed on helix B (see chapter IV for details), where the main effect of 
the mutation was on the rate of recovery from desensitization and co-expression with 
stargazin had reduced effects on stead-state desensitization and kainate efficacy (see 
below). 
5.3.2 Stargazin’s effect on constructs carrying mutations in M1 and M4 linkers differs 
depending on the construct. 
To identify the role that stargazin plays in AMPA receptor desensitization, all the 
constructs described in Table 5.1 were co-expressed with stargazin. Stargazin was able to 
potentiate trafficking of all four constructs, indicating that the associatin responsible for 
trafficking is maintained (Figure 5.2 I). In mutations that decrease the amount of 
desensitization, (e.g., A518S/Y519P and V788I), stargazin was able to further decrease % 
desensitization (Figure 5.2 G and J), as well as speed recovery from desensitization 
(Figure 5.2 G and K), and increase kainate efficacy (Figure 5.2 L). Stargazin’s effects on 
desensitization were at least additive, and maybe synergistic, with these mutations that 
decreased steady-state desensitization, indicating that they did not affect he ability of 
stargazin to associate with the AMPA receptor.  
Mutations K501A/K502A and S784G/A789G had a surprising result. Stargazin was 
unable to increase glutamate steady-state current in these constructs (Figure 5.2 C, E and 
J).  
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Although stargazin did significantly speed the rate of recovery from desensitization in 
K501A/K502A, it was not equivalent to the level of GluR1 co-expressed with stargazin. 
However, stargazin was unable to speed the rate of recovery from desensitization in 
S784G/A789G mutant construct (Figure 5.2 D, F and K). Co-expression with stargazin in 
both K501A/K502A and S784G/A789G also resulted in significantly reduced kainate 
efficacy when compared to GluR1 co-expressed with stargazin (Figure 5.2 L). Overall 
these results indicate that stargazin was unable to elicit its full effect on mutant constructs 
K501A/K502A and S784G/A789G, while having no problems doing so for 
A518S/Y519P and V788I. Because mutant construct S784G/A789G had the most 
profound phenotype when co-expressed with stargazin, where stargazin had no effect on 
% desensitization or rate of recovery from desensitization, and a diminished effect on 
kainate efficacy, we suggest that these residues are candidates for an association point 
with stargazin. The K501A/K502A mutant construct, when co-expressed with stargazin, 
had a less profound phenotype suggesting that these residues are most likely participating 
in transduction of stargazin’s effects on the AMPA receptor. 
5.3.3 Constructs carrying mutations in intracellular loop 2 of the AMPA receptor 
exhibit a phenotype with slowed recovery from desensitization. 
Previous results from our laboratory indicated that the C-terminal cytoplasmic tail of 
stargazin was partially responsible for AMPA receptor trafficking, desensitization and 
kainate efficacy (Turetsky et al., 2005), while more recent research indicates th t 
stargazin’s intracellular loop and N-terminus also play a role in AMPA receptor function 
(Milstein and Nicoll, 2009). In our attempt to identify intracellular regions of the AMPA 
receptor important for stargazin association, we mutated residues that were conserved 
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among AMPA receptors, but not kainate receptors, in the first and second intracellular 
loops of GluR1. Multiple mutations made in the first extracellular loop of the AMPA 
receptor yielded no significant findings (see table 5.1 for details). In contrast, mutations 
in the 2nd intracellular loop had clear desensitization phenotypes. Three of the mutations 
in the 2nd intracellular loop: S588M, S591A and G594T trafficked significantly less than 
control GluR1 (Figure 5.3 I). All constructs exhibited normal % desensitization (Fgure 
5.3 J) and rate of desensitization onset (data not shown). However, the rates of recovery 
from desensitization in these mutants were significantly increased (Figure 5.3 D, F, H and 
K), indicating that mutations of AMPA residues to kainate residues in the 2nd intracellular 
loop promote a kainate-like desensitization phenotype (i.e., slower recovery from 
desensitization). Interestingly, mutation of residue R595 to either alanine or serine (the 
naturally occurring mutation in GluR3 that leads to mental retardation (Wu et al., 2007)) 
resulted in a construct that was not functional, indicating that this residue is crucial for 
AMPA receptor channel function. Although G594T was functional when expressed 
homomerically, mutations of G594 to phenylalanine or lysine also resulted in non-
functional receptors. Of all the mutations that we prepared for this dissertation only a 
single other mutation (cysteine at position 760) resulted in a non-functional receptor. The 
rarity of this occurrence suggests to us that the effects of G594T on AMPA receptor 




Figure 5.3: Mutations in the 2nd intracellular loop affect AMPA receptor desensitization. 
Representative traces for constructs alone (black) and co-expressed with stargazin 
(lavender) in response to glutamate in the presence and absence of TCM for GluR1 (A), 
S588M (C), S591A (E) and G594T (G). Traces to a 3 step protocol demonstrate recovery 
from desensitization of GluR1 (B), S588M (D), S591A (F) and G594T (H) expressed 
alone (black) or with stargazin (lavender). Summary of the results of trafficking as 
measured by whole cell currents to application of Glutamate + TCM normalized to whole 
cell capacitance (I); Percent desensitization is measured relative to glutamate + TCM 
peak (J); The time constant of recovery from desensitization is represented by the slow 
component of a two exponential fit of the TCM on-rate in the presence of glutamate (K) 
and Kainate efficacy as measured by normalizing the kainate current to Glutamate + 
TCM peak (L) are represented by bar graphs illustrating means ± SEM, n = 12-38. * 
indicates statistical difference within each constructs, # indicates statistical difference 
compared to GluR1 expressed alone, $ indicates significance as compared to GluR1γ2. (* 
P<0.05; ** P<0.01; ***P<0.001). 
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5.3.4 Mutations in the 2nd intracellular loop of GluR1 reduce stargazin’s effect on 
AMPA receptor desensitization and kainate efficacy.  
In order to elucidate areas of the AMPA receptor important for association with 
stargazin, we co-expressed constructs carrying mutations in the intracellular loop 2 with 
stargazin. Stargazin was able to significantly potentiate trafficking of all mutant 
constructs, indicating that the association that is important for trafficking is preserved 
(Figure 5.3 I). Although stargazin was able to increase the steady-state current and thus 
decrease the % desensitization in all constructs carrying mutations in intracellular loop 2, 
it was significantly less efficacious at doing so as compared to control GluR1 (Figure 5.3 
C, E, G and J). However, stargazin was able to elicit its full effect on the rate of recovery 
from desensitization in these mutants (Figure 5.3 D, F, H and K). Kainate efficacy was 
significantly increased by co-expression with stargazin in all three constructs; however, 
the degree to which differed between mutant constructs (Figure 5.3 L). Interestingly, both 
S588M and S591A co-expressed with stargazin had significantly reduced kainate efficcy 
compared to control stargazin, indicating that stargazin was unable to elicit its full effect 
on kainate efficacy in these mutants. Because of the partial loss of effect on % 
desensitization and kainate efficacy, with preserved trafficking and speeding of recovery 
from desensitization, we propose S588 and S591 as candidate sites of interaction with the 
intracellular portions of stargazin responsible for modulation of receptor gating (M lstein 
and Nicoll, 2009). 
5.4 Summary of results 
In our quest to find areas of the AMPA receptor that participate in association wi h 
stargazin we have uncovered some unexpected results: 
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• Residues S784 and A789 located in the M4 linker of GluR1 are candidates for 
association with stargazin. 
• Residues S588 and S591 located in the 2nd intracellular loop of GluR1 may also 
play a role in associating with the intracellular portions of stargazin. 
• Mutation of residues K501/K502 in the M1 linker and S588, S591 in the 2nd 
intracellular loop of the AMPA receptor result in constructs with a slowed rate 
of recovery from desensitization. 
• Mutations immediately adjacent to the membrane in linkers M1 or M4 
(A518S/Y519P and V788I) produced AMPA receptors with decreased steady-
state desensitization, but normal onset and recovery kinetics, suggesting these 
residues are important for receptor gating. Stargazin was able to exert its full 
effect on these mutant AMPA receptors. 
• Partial loss of effects of stargazin on desensitization and kainate efficacy in the 
K501A/K502A mutation, located in the M1 linker, suggest these residues 
participate in the transduction of stargazin’s effects on the AMPA receptor. 
• The association between the AMPA receptor and stargazin responsible for 
trafficking was preserved in all of the mutant constructs described. 
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CHAPTER VI 
IDENTIFICATION OF RESIDUES IN STARGAZIN THAT MEDIATE EFFECTS ON 
AMPA RECEPTOR DESENSITIZATION AND KAINATE EFFICACY 
6.1 Introduction 
TARPs have been shown to have multiple effects on AMPA receptor trafficking and 
function. Originally, TARPS were implicated in increasing AMPA receptor trafficking 
and targeting AMPA receptors to the synapse (Chen et al., 2000). Subsequently, TARPS
were shown to affect the biophysical properties of the AMPA receptor, reducing agonist-
evoked receptor desensitization, slowing receptor deactivation, potentiating kainate 
responses and increasing relative frequency of large conductance openings (Priel et al., 
2005; Tomita et al., 2005b; Turetsky et al., 2005; Zhang et al., 2006). Stargazin also 
increases the binding rate for positive allosteric modulators in the presence of agonist. 
Because these modulators only bind to AMPA receptors in the non-desensitized state, 
this suggests that TARPs speed AMPA receptor recovery from desensitization.  
Original chimeric exchanges between γ2 and γ5 identified the first extracellular 
domain of stargazin as important for stargazin’s effect on AMPA receptor desensitization 
and kainate efficacy and the C-terminal cytoplasmic tail important for receptor trafficking 
(Tomita et al., 2005b). Work from our laboratory suggested that this dissociation of 
stargazin effects is not complete and that the extracellular loop 1 of stargazin also has a 
role in trafficking of the AMPA receptor, while the C-terminal cytoplasmic tail has a role 
in kainate efficacy and desensitization (Turetsky et al., 2005). Although majordomains 
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of stargazin that mediate AMPA receptor trafficking and function have been recognized, 
the mechanism of stargazin’s action, as well as specific residues that medie this 
mechanism and specific points of association between stargazin and the AMPA receptor, 
remains unknown. 
Based on previous experiments from our laboratory (Figure 1.11 and 6.1), we utilized 
chimeric exchanges in the first extracellular domain between the canonil TARP γ2 and 
γ5, which was originally thought to have no function in AMPA receptors (Figure 6.1 A). 
The largest exchange between stargazin and γ5, Ex (26-103), which exchanged almost all 
of the first extracellular loop, generated a chimeric protein that lost most of it  ability to 
potentiate kainate efficacy and decrease AMPA receptor desensitization, while also 
having significantly decreased trafficking (Figure 6.1 B, C and D). Exchange of th  distal 
portion of the extracellular loop Ex (89-103) produced a protein that was not significantly 
different from stargazin in its effects on AMPA receptor desensitization nd kainate 
efficacy (Figure 6.1 C and D), while chimeric exchange Ex (61-103) (data not shown) 
resulted in a protein that lost its ability to elicit its effects on AMPA receptor 
desensitization, kainate efficacy and trafficking. Therefore we assumed that this construct 
was not functional.  
Upon close inspection of the protein sequence of all TARPs we noted that Class I 
TARPs (γ2, γ3, γ4 and γ8) had a total of four cysteines in the first extracellular loop in 
positions 40, 67, 68 and 77, while the members of Class II TARPs (γ5 and γ7) had only 
two cysteines in positions 67 and 77. Interestingly, two cysteines in positions 67 and 77 
were conserved even among non-TARPs γ1 and γ6 (for details see figure 6.2). Based on 
these observations we hypothesized that the first extracellular loop of stargazin might 
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undergo disulfide bonding and that the correct number of cysteines was crucial for proper 
protein structure. The non-functional Ex (61-103) had three cysteines in the first 
extracellular loop, with phenylalanine at position 68. Mutating F68 to a cysteine restored 
the TARP pattern of four cysteines and created a functional construct. The new construct 
Ex (61-103)/F68C had normal trafficking and desensitization but kainate efficacy was 
reduced approximately 60% relative to stargazin (Figure 6.1). 
 
Figure 6.1: Chimeric exchanges between γ2 and γ5 identify areas of the first extracellular 
loop important for stargazin’s effects on desensitization and kainate efficacy. St rgazin 
schematic, delineating residues bordering chimeric exchanges (A), Summary of the 
results of trafficking as measured by whole cell currents to application of Glutamate + 
TCM normalized to whole cell capacitance (B); Percent desensitization is measured 
relative to glutamate + TCM peak (C); and Kainate efficacy as measured by normalizing 
the kainate current to Glutamate + TCM peak (D) are represented by bar graphs 
illustrating means ± SEM, n = 12-18. * indicates statistical difference within each 
constructs, # indicates statistical difference compared to GluR1 expressed alon , $ 
indicates significance as compared to GluR1γ2. (** P<0.01; ***P<0.001). 
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Because the construct was functional after the introduction of the 4th cysteine, it 
suggested to us that disulfide bonding might play a role in the function of stargazin 
(Figure 6.1 B and C). These results further suggested that residues important for k inate 
efficacy are located between amino acids 26 and 89, while residues important for 
modulation of AMPA receptor desensitization are located between residues 26 and 61. 
To further address the functional effect of the extracellular portion of the prot in, we 
turned to site-directed mutagenesis as a tool for identification of amino acids important 
for stargazin’s effect on AMPA receptor function. Our lab is especially interested in the 
association sites between stargazin and AMPA receptors, therefore we initially focused 
on polar residues. 
The loss of association on the extracellular portion of stargazin would most likely 
present with a phenotype similar to Ex(26-103): almost complete loss of stargazin’s 
effect on desensitization and kainate efficacy with a small decrease in trafficking. It is 
also possible that some of the residues that we select for site-directed mutagenesis would 
affect conformational changes in stargazin, in which case only a partial loss of the 
functional effects of stargazin would be observed. 
To select residues for site-directed mutagenesis we used homology between subunits 
in the γ (CACNG) family, which currently has 8 members. Initially it was thought that γ2 
and γ3 were more important in their function on AMPA receptors, therefore we 
concentrated on residues that were conserved in γ2 and γ3, but different in γ5 (indicated 
in yellow in Figure 6.2). As the TARP field evolved, it became clear that both γ4 and γ8 
also played important roles in AMPA receptor physiology, therefore γ4 and γ8 joined γ2 





Figure 6.2:  Stargazin schematic (top) and sequence alignment (bottom) indicating 
residues of interest in the extracellular domains of stargazin. 
       polar residues conserved exclusively throughout class I TARPs.  
       polar residues conserved only in γ2 and γ3. 
       cysteines that may play a role in disulfide linkages. 
       residues conserved in both classes of TARPs as well as γ1 and γ6.  
       polar residues conserved in both classes of TARPs but not γ1 and γ6.  
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Thus, we selected residues that were conserved in all class I TARPS, but differed in γ5 
(indicated in red in Figure 6.2).  
Most recently, the class II TARPs, γ5 and γ7, were demonstrated to have small but 
significant, functional effects on AMPA receptors (Kato et al., 2007; Soto et al., 2007; 
Kato et al., 2008; Soto et al., 2009). This discovery led us to our final set of residues that 
were conserved in all TARPs but differed in voltage-gated calcium channel subunits γ1 
and γ6 (illustrated in magenta in Figure 6.2). As discussed above, we knew that cysteines 
(indicated in blue on Figure 6.2) appear to be crucial for the function of stargazin; 
therefore we selected all 4 cysteine residues for site-directed mutagenesis (illustrated in 
blue in figure 6.2). 
The role of glycosylation in AMPA receptors is controversial, where some reports 
indicate the importance of glycosylation in agonist binding (Kawamoto et al., 1995), 
while others indicate that AMPA receptors can function in the absence of glyc sy ation 
(Everts et al., 1997). Stargazin has consensus sites for N-linked glycosylation (NETS) 
(TS residues of the NETS motif are illustrated in yellow in Figure 6.2) and C-linked 
mannosylation (GLWRTC) (GLWR residues of the motif are illustrated in green in 
Figure 6.2). Although, the role of glycosylation in TARPs is unknown, deletion of N-
linked glycosylation in γ1 does not alter its function (Arikkath et al., 2003), while 
deletion of C-mannosylation in MP-20 (a transmembrane protein distally related to 
TARPs) results in a construct that is unable to interact with other proteins (Ervin et al., 
2005). Therefore we also selected these motifs for site-directed mutagenesis. 
 For completion, we selected residues in stargazin’s extracellular loop 2 that were 
both conserved within class I TARPs and both classes of TARPs but not in γ1 and γ6. 
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Interestingly, earlier studies that examined the role of extracellular oop 2 in AMPA 
receptor function and concluded that it was not important also utilized chimeric 
exchanges between γ1 and γ5 (Tomita et al., 2005a). Recent insights into the role of γ5 
on the function of AMPA receptor directed us to re-evaluate the role of second 
extracellular loop of stargazin.  
6.2 Statement of purpose 
We mutated a number of residues in the first and second extracellular loops of 
stargazin in order to identify amino acids that play a role in stargazin’s effect on AMPA 
receptor desensitization and kainate efficacy.  
6.3  Results and Discussion 
Table 6.1 summarizes the constructs made and their effects on AMPA receptor 
trafficking, desensitization and kainate efficacy. Several of the construct  did not have a 
phenotype that was different from stargazin and thus will not be discussed in the data 
presentation below. One of the double mutations, Y89L/E90T, introduced a slight gain of 
function on AMPA receptor desensitization (Table 6.1), while 3 other mutations (T59A, 
E70A and D86N/D88Q) had significant, but modest effects on AMPA receptor 
desensitization and kainate efficacy (Table 6.1). Such changes are unlikely to be 












Table 6.1: Residues in stargazin that affect its desensitization and kainate effects 
on AMPA receptor 
Mutation N % Desensitization Kainate Efficacy Trafficking 
Control        
GluR1 61 99.25 0.003 0.144 
GluR1 + stargazin 72 94.27 *** 0.536 *** 0.509 *** 
1st EC loop Cysteines        
C40I 12 94.72 *** 0.453 $$ *** 0.615 *** 
C67A 12 99.61  $$ 0.003 $$$ 0.190 $$ 
C68F 15 91.59 *** 0.557 *** 0.375 *** 
C77A 12 98.98 $$ 0.0202 $$$ 0.423 *** 
1st EC loop GLWXXC        
W64A 22 96.72 ** 0.339 $$$ *** 0.526 *** 
H60F/W64A/R65L 16 99.26 $$ 0.007 $$$ 0.246 $$ 
1st EC loop NETS        
T50A/S51A 9 83.51 $$ *** 0.643 $$ *** 0.670 *** 
1st EC loop residues        
S36A 17 95.68 *** 0.269 $$$ *** 0.421 * 
R37A 12 93.94 *** 0.507 *** 0.466 ** 
K41A/K43A 7 93.22 *** 0.497 *** 0.612 *** 
T42A/S44A 5 95.13 *** 0.545 *** 0.531 *** 
S46A 10 97.99 0.26 $$$ *** 0.401 *** 
K52A/K53A 6 92.75 *** 0.511 *** 0.451 ** 
T59A 9 97.36  0.453 *** 0.511 ** 
E70A 6 95.65 *** 0.429 $ *** 0.850 $$$*** 
K74A 6 93.61 *** 0.543 *** 0.617 *** 
H82Y 8 91.56 *** 0.568 *** 0.456 ** 
D86N/D88Q 6 95.15 ** 0.435 $ *** 0.437 * 
Y89L/E90T 7 85.68 $$$ *** 0.578 0.530 ** 
R99A 6 98.15 0.371 $ *** 0.498 ** 
R102A 6 93.62 *** 0.537 *** 0.537 *** 
S104A/S105T/I106P 7 95.19 *** 0.358 $$ *** 0.613 *** 
S36A/S104A/S105T/I106P 14 98.42 $$ 0.116 $$$ * 0.584 * 
S36A/S46A 9 94.06 ** 0.38 $$ *** 0.748 *** 
2nd EC loop residues        
Y155M 11 97.56 $ 0.352 $ *** 0.459 *** 
I156R/S157Q 11 95.6 * 0.388 $ *** 0.421 *** 
N159V 12 96.75 0.444 *** 0.527 *** 
P163M 6 95.83 *** 0.619 *** 0.586 *** 
K165A 5 96.98 *** 0.607 *** 0.734 *** 
S174A 6 94.92*** 0.543 *** 0.791 *** 
Table 6.1: Average Desensitization, Kainate Efficacy and Trafficking for the above 
mutations are given (n=12-70). Yellow highlighting indicates mutations that had loss of 
stargazin function; magenta highlighting indicates gain of stargazin function. Statistics 
were performed with One-Way ANOVA and Student-Newman-Keuls post-hoc test 
compared to experimentally matched controls. $ indicates statistical difference compared 
to GluR1 co-expressed with stargazin, * indicates statistical differenc compared to 
GluR1 alone (* P<0.05; ** P<0.01; *** P< 0.001) 
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6.3.1  Mutation of the cysteines in the first extracellular loop of stargazin result in 
constructs that have trafficking, desensitization and kainate efficacy deficits. 
Based on the preliminary results from our laboratory indicating that cysteine in the 
first extracellular loop of stargazin are important for the protein’s ability to function, we 
mutated two of the cysteines that were conserved (C40 and C68) only in class I TARPs to 
their corresponding residue in γ5 (resulting in C40I and C68F). We also mutated two 
cysteines that were conserved thoughout both classes of TARPs, as well as γ1 and γ6, 
(C67 and C77) to alanines (resulting in C67A and C77A). These constructs were co-
expressed with homomeric GluR1 for electrophysiological analysis, and evaluat d on 
their ability to affect AMPA receptor trafficking, desensitization and kainate efficacy.  
γ2 (C67A) was unable to potentiate trafficking, or affect AMPA receptor 
desensitization or kainate efficacy, suggesting that it was non-functional (Figure 6.3 G, 
H, I and J). Other stargazin constructs γ2 (C40I), γ2 (C68F) and γ2 (C77A) were able to 
significantly increase the trafficking of homomeric GluR1 as compared to GluR1 alone 
(Figure 6.3D). Functional effects of stargazin on AMPA receptor desensitization and 
kainate efficacy were significantly impaired by the C77A point mutation, resulting in a 
construct that did not significantly reduce glutamate desensitization or increase kainate 
efficacy relative to GluR1 control (Figure 6.3 H, I and J). Mutant constructs γ2 (C40I) 
and γ2 (C68F) were comparable to wild-type stargazin co-expressed with GluR1 in their 
effect on % desensitization (Figure 6.3I) although γ2 (C40I) was slightly impaired in its 
effect on kainate efficacy (Figure 6.3 H). Consistent with the lack of effects on % 
desensitization construct γ2 (C67A) and γ2 (C77A) had no significant effect on the rate 
of recovery from desensitization (Figure 6.3 J). 
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Figure 6.3: Mutation of cysteines in the first extracellular loop affect stargazin’s 
function. Representative responses to glutamate in the presence and absence of TCM and 
kainate for GluR1 expressed alone (black) and co-expressed with stargazin (lavender) 
(A), GluR1 co-expressed with γ2 (C67A) (B) and GluR1 co-expressed with γ2 (C77A) 
(C). Representative responses to a 3 step protocol for GluR1 expressed alone (black) and 
with stargazin (lavender) (D), GluR1 co-expressed with γ2 (C67A) (E) and GluR1 co-
expressed with γ2 (C77A) (F). Summary of the results of trafficking as measured by 
whole cell currents to application of Glutamate + TCM normalized to whole cell 
capacitance (G); Kainate efficacy as measured by normalizing the kainate current to 
Glutamate + TCM peak (H); Percent desensitization is measured relative to glutamate + 
TCM peak (I); The time constant of recovery from desensitization is repres nted by the 
slow component of a two exponential fit of the TCM on-rate in the presence of glutamate 
(J) are represented by bar graphs illustrating means ± SEM, n = 12-21. * indicates 
statistical difference compared to GluR1 alone, $ indicates significance compared to 
GluR1γ2. (* P<0.05; ** P<0.01; ***P<0.001). 
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Interestingly, γ2 (C77A), a single amino acid substitution, had almost as profound a 
phenotype as Ex(26-103), which exchanges the first extracellular loop. Because γ2 
(C67A) also had a profound phenotype with complete loss of all function, while γ2 
(C68F) and γ2 (C40I) phenotypes were almost indistinguishable from control γ2, we 
propose that disulfide bonding occurs between cysteine residues 67 and 77, thus 
maintaining the proper tertiary structure of the protein. Because C67 is a part of the 
mannosylation motif (see section 6.3.2) we cannot rule out that much of its phenotype is 
caused by the loss of the conserved motif for mannosylation.  
6.3.2 Mutation of the consensus N-linked glycosylation motif enhances the effect of 
stargazin on desensitization and kainate efficacy. 
TARPs are known to be glycosylated (Deng et al., 2006), but the location and type of 
glycosylation is unknown. A single consensus site for N-linked glycosylation exists in 
stargazin at residues 48-NETS-51. To elucidate the role of glycosylation on the function 
of stargazin we mutated residues T50 and S51 to alanines to alter this consensus site.  
The resulting construct γ2 (T50A/S51A) had enhanced effects on AMPA receptor 
desensitization and kainate efficacy (Figure 6.4 D and E), while entirely preserving the 
trafficking function of stargazin (Figure 6.4 C). We are currently in the process of 
characterizing another mutant construct in the consensus site γ2 (N48Q). If the results of 
this mutation have a similar phenotype to γ2 (T50A/S51A), it would suggest that 
removing the consensus site for glycosylation allows for better association of stargazin 
with the AMPA receptor and/or increased function of stargazin. Loss of glycosylation in 
these constructs will have to be confirmed with protein biochemistry. 
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Figure 6.4: Mutation of residues in the conserved glycosylation motif NETS result in 
gain of function. Representative responses to glutamate +/- TCM and kainate for GluR1 
expressed alone (black) and co-expressed with stargazin (lavender) (A) and GluR1 co-
expressed with γ2 (T50A/S51A) (B). Summary of the results of trafficking as measured 
by whole cell currents to application of Glutamate + TCM normalized to whole cell 
capacitance (C); Kainate efficacy as measured by normalizing the kainate current to 
Glutamate + TCM peak (D); and Percent desensitization is measured relative to 
glutamate + TCM peak (E) are represented by bar graphs illustrating means ± SEM, n = 
9-15. * indicates statistical difference compared to GluR1 alone, $ indicates significance 
compared to GluR1γ2. (* P<0.05; ** P<0.01; ***P<0.001). 
 
6.3.3 Mutation of the conserved motif GLWXXC in the first extracellular loop of 
stargazin results in constructs with deficits in trafficking, desensitization nd 
kainate efficacy. 
All of the subunits in the CACNG family share a common motif GLWXXC (in γ2 
residues 62-67). This motif is also present in claudins and the more distally related 
tetraspannins. These include the peripheral myelin protein 22 (PMP-22), mutations of 
which are implicated in inherited peripheral neuropathies and eye lens specific membrane 
protein 20 (MP20) of unknown function. This motif is a consensus site for C-linked 
mannosylation of the tryptophan (W) residue and is known to be mannosylated in PMP22 
and MP20. In stargazin, this motif consists of GLWRTC and it is unknown whether this 
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motif is mannosylated or plays another role in the function of the protein. Using internet 
software (NetCGlyc available from www.expasy.org), we examined the sequence of the 
entire first extracellular loop of stargazin and scored the possibility of mannosylation at 
0.422 (with 0.5 being mannosylated). To elucidate the role of this motif, we mutated 
residue W64 to alanine and also created a more extensive mutation that combined W64A 
mutation with residues H60 and R65 changed to their corresponding γ5 residues 
phenylalanine and leucine respectively. 
Interestingly, the triple mutation of stargazin (H60F/W64A/R65L) was unable to 
potentiate trafficking, decrease the desensitization or increase kainate efficacy of 
homomeric GluR1. (Figure 6.5 G, H, I and J) The single amino acid substitution W64A 
in stargazin resulted in a construct that was able to increase trafficking and reduce 
desensitization of GluR1 comparable to a control GluR1 co-expressed with stargazin 
(Figure 6.5 G and I). Although kainate efficacy was significantly increased with γ2, 
(W64A), it was reduced compared to GluR1 co-expressed with stargazin (Figure 6.5 H).  
In contrast to its effect on steady-state desensitization, γ2 (W64A) was unable to speed 
the rate of recovery from desensitization (Figure 6.5 B and J). 
Because the triple mutations H60F/W64A/R65L had no functional effects on 
glutamate desensitization, kainate efficacy or trafficking, we did not anticipate that it 
would have an effect on the rate of recovery from desensitization. Interestingly, γ2 
(H60F/W64A/R65L) slowed the rate of recovery from desensitization as compared to 
control GluR1 expressed alone (Figure 6.5 C and F), in a direction opposing that of 
normal stargazin function. 
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Figure 6.5: Mutation of residues in conserved motif GLWXXC affect stargazin’s 
function. Representative responses to glutamate +/- TCM and kainate for GluR1 
expressed alone (black) and co-expressed with stargazin (lavender) (A), GluR1 co-
expressed with γ2 (W64A) (B) and GluR1 co-expressed with γ2 (H60F/W64A/R65L) 
(C). Representative responses to a 3 step protocol for GluR1 expressed alone (black) and 
with stargazin (lavender) (D), GluR1 co-expressed with γ2 (W64A) (E) and GluR1 co-
expressed with γ2 (H60F/W64A/R65L) (F). Summary of the results of trafficking as 
measured by whole cell currents to application of Glutamate + TCM normalized to whole 
cell capacitance (G); Kainate efficacy as measured by normalizing the kainate current to 
Glutamate + TCM peak (H); Percent desensitization is measured relative to glutamate + 
TCM peak (I); The time constant of recovery from desensitization is repres nted by the 
slow component of a two exponential fit of the TCM on-rate in the presence of glutamate 
(J) are represented by bar graphs illustrating means ± SEM, n = 9-16. * indicates 
statistical difference compared to GluR1 alone, $ indicates significance compared to 
GluR1γ2. (* P<0.05; ** P<0.01; ***P<0.001). 
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Although γ2 (H60F/W64A/R65L) was seemingly non-functional, this result suggests 
that it was still able to associate with the AMPA receptor on the cell surface, and affect 
its function. Although it appears that at least some of these mutant constructs asso iate 
with the AMPA receptor, it is possible that mannosylation and/or the conserved motif 
might play a role in forward trafficking of the receptor. Therefore, it is possible that only 
a very small fraction of the receptors are associated with γ2 (H60F/W64A/R65L). 
Surface biotinylation studies will be needed to quantify the amount of GluR1 and γ2 
(H60F/W64A/R65L) on the surface and further explore the role of this motif in forward 
trafficking.  
Because the W64A mutation, which eliminates the tryptophan residue that supports 
C-linked mannosylation, had only a partially affected phenotype, while γ2 
(H60F/W64A/R65L) and C67A were totally non-functional, we suspect that it is the 
GLWRTC motif itself, rather than mannosylation, that is necessary for proper tertiary 
structure. 
6.3.4 Mutation of conserved polar residues proximal to the plasma membrane in the 
first extracellular loop of γ2 reduces effects of stargazin on AMPA receptor 
desensitization and kainate efficacy. 
Stargazin shares multiple conserved polar residues and motifs with other proteins in 
the TARP family. To elucidate the role of these residues on the function of stargazin, we 
mutated the majority of the conserved residues in the first extracellular loop of stargazin 
(illustrated in Figure 6.2) to either alanines or their corresponding residues in γ5. The 
summary of resulting mutations is presented in Table 6.1.  
 101
Mutations that produced functional deficits in stargazin included: S36A, S46A, R99A 
and S104A/S105T/I106P. The trafficking function of all these mutant constructs was 
preserved (Figure 6.6 G). While all four of these mutations presented with decreased 
kainate efficacy (Figure 6.6 H), only S46A and R99A presented with decreased effect on 
steady-state desensitization (Figure 6.6 I). Consistent with this effecton % 
desensitization, γ2 (S46A) and γ2 (R99A) were also not able to significantly speed the 
rate of recovery from desensitization of GluR1 (Figure 6.6 J). We also combined 
mutations with partial phenotypes making constructs γ2 (S36A/S46A) and γ2 
(S36/S104A/S105T/I106P) that were both able to significantly increase trafficking of 
GluR1 (Figure 6.6 G). The combination γ2 (S36A/S46A) presented with a phenotype 
similar to γ2 (S36A) with decreased kainate efficacy but normal effect on steady-state 
desensitization and partial effect on recovery from desensitization (Figure 6.6 H, I and J).  
Combination of mutations S36A and S104A/S105T/I106P, 
γ2(S36/S104A/S105T/I106P), presented with a phenotype that exhibited further 
reduction in kainate efficacy (Figure 6.6 H) and an additive and possibly synergistic 
effect on steady-state desensitization (Figure 6.6 I). Consistent with this effect on % 
desensitization, this construct was unable to speed the recovery from desensitization 
(Figure 6.6 J). Overall, these results indicate that stargazin residues S36, S104, S105 and 
I106 located in the regions proximal to the plasma membrane of the first extracellular 




Figure 6.6: Mutation of residues proximal to the membrane in the 1st EC loop affect 
stargazin’s function. Representative responses to glutamate +/- TCM and kainate for 
GluR1+γ2 (S46A) (A), GluR1+γ2 (R99A) (B), GluR1+γ2 (S36A/S104A/S105T/I106P) 
(C). Representative responses to a 3 step protocol for GluR1+γ2 (S46A) (D), GluR1+γ2 
(R99A) (E), GluR1+γ2 (S36A/S104A/S105T/I106P) (F). Summary of the results of 
trafficking as measured by whole cell currents to application of Glutamate + TCM 
normalized to whole cell capacitance (G); Kainate efficacy as measured by normalizing 
the kainate current to Glutamate + TCM peak (H); Percent desensitization is measured 
relative to glutamate + TCM peak (I); The time constant of recovery from desensitization 
is represented by the slow component of a two exponential fit of the TCM on-rate in the 
presence of glutamate (J) are represented by bar graphs illustrating mea s± SEM, n = 7-
28. * indicates statistical difference compared to GluR1 alone, $ indicates significance 
compared to GluR1γ2. (* P<0.05; ** P<0.01; ***P<0.001). 
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6.3.5 Mutation of conserved polar residues proximal to the plasma membrane in the 
second extracellular loop of γ2 reduces effect of stargazin on AMPA receptor 
desensitization and kainate efficacy. 
To be complete, we examined the second extracellular loop of stargazin and selected 
polar residues that were conserved within class I TARPs but not in class II TARPs 
(illustrated in red in Figure 6.2) as well as residues that were conserved among ll TARPs 
but not in γ1 or γ6 (illustrated in magenta in Figure 6.2). Residues that were only 
conserved in class I TARPs did not have significantly different phenotype when 
compared to stargazin (see Table 6.1 for details), however, residues that were cons rved 
in all TARPs (Y155, I156 and S157) did have a significantly different phenotype when 
mutated to their corresponding γ1 residues.  
 Two constructs carrying mutations in the conserved regions of both classes of 
TARPs γ2 (Y155M) and γ2 (I156R/S157Q) were able to increase trafficking of GluR1 
2.5-3 fold comparable to wild-type stargazin (Figure 6.7 G). Both constructs presented 
with decreased kainate efficacy (Figure 6.7 H), while only γ2 (Y155M) was not able to 
decrease steady-state desensitization (Figure 6.7 I). Neither construt was able to speed 
the rate of recovery of GluR1 from desensitization (Figure 6.7 J).  
Interestingly, γ2 (I156R/ S157Q) had an unexpected effect on kainate currents (Figure 
6.7 C). The shape of the kainate response was affected, such that the onset of the 
response was significantly slowed. However, stargazin did not affect kainate b ding, but 
instead increased its efficacy, suggesting that mutation I156R/ S157Q may introduce 
changes in gating properties of the channel that may slow the step-wise increases of 
conductance states (Rosenmund et al., 1998). 
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Figure 6.7: Mutation of residues proximal to the membrane in the 2nd EC loop affect 
stargazin’s function. Representative responses to glutamate +/- TCM and kainate for 
GluR1 expressed alone (black) and co-expressed with stargazin (lavender) (A), 
GluR1+γ2 (Y155M) (B) and GluR1+γ2 (I156R/S157Q) (C). Representative responses to 
a 3 step protocol for GluR1 expressed alone (black) and with stargazin (lavender) (D), 
GluR1+γ2 (Y155M) (E) and GluR1+γ2 (I156R/S157Q) (F). Summary of the results of 
trafficking as measured by whole cell currents to application of Glutamate + TCM 
normalized to whole cell capacitance (G); Kainate efficacy as measured by normalizing 
the kainate current to Glutamate + TCM peak (H); Percent desensitization is measured 
relative to glutamate + TCM peak (I); The time constant of recovery from desensitization 
is represented by the slow component of a two exponential fit of the TCM on-rate in the 
presence of glutamate (J) are represented by bar graphs illustrating mea s± SEM, n = 11-
16. * indicates statistical difference compared to GluR1 alone, $ indicates significance 
compared to GluR1γ2. (* P<0.05; ** P<0.01; ***P<0.001). 
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The phenotypes of the mutant constructs γ2 (Y155M) and γ2 (I156R/S157Q) in the 
second extracellular loop of stargazin are similar to those of mutations in the regions 
proximal to the plasma membrane on the first extracellular loop of stargazin. This result 
indicates that residues close to the membrane in both loops of stargazin are important for 
its functional effects on the AMPA receptor. 
6.4 Summary of the results 
Our exploration of the stargazin molecule with site-directed mutagenesis and 
electrophysiology revealed a number of regions in stargazin that play a role in its ffects 
on desensitization and kainate efficacy. 
• Cysteines conserved among all members of the γ subunit family are crucial for 
the function or stability of stargazin. 
• Destruction of the consensus motif for N-linked glycosylation results in a gain 
of function for kainate efficacy and desensitization. 
• The conserved motif GLWXXC is essential for the function of stargazin. 
• Polar residues located proximal to the membrane in the first and second 
extracellular loops of stargazin play an important role in stargazin’s effects on 




DISCUSSION AND CONCLUSIONS 
For these experiments we made 44 mutations on the AMPA receptor, only 9 of which 
have been previously reported, and 45 targeted mutations in stargazin. Previous research
with stargazin always involved chimeric exchanges, making our study the most 
comprehensive mutagenesis on both the AMPA receptor and stargazin to date.  
AMPA receptor desensitization is crucial for shaping the time course of synaptic 
transmission. Previous studies involving AMPA receptor desensitization primarily 
focused on the residues on the intra-dimer interface. These studies were able to elucidate 
the mechanism of desensitization onset, but did not further our knowledge of the 
mechanism of AMPA receptor recovery from desensitization. Examining mutations that 
we made in both the AMPA receptor and stargazin allowed us to suggest a novel 
mechanism for AMPA receptor recovery from desensitization and to identify candidate 
association sites between AMPA receptors and stargazin. 
7.1  What we learned about stargazin. 
In our attempt to understand the mechanism of stargazin’s action on AMPA receptor 
function, as well as to identify association sites between the two proteins, we made 
multiple mutations in both the AMPA receptor and stargazin. The experiments confirmed 
that stargazin acts by speeding AMPA receptor recovery from desensitization and 
identified three possible sites in the AMPA receptor involved in association with 
stargazin, and refined the areas of stargazin important for efficacy.
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7.1.1 Stargazin’s mechanism of action is distinct from that of cyclothiazide and the 
L479Y mutation. 
Previous studies by Sun and colleagues (2002) proposed a precise mechanism for the 
process of AMPA receptor desensitization based on observations from the crystal 
structure. Horning and Mayer (2004) confirmed this mechanism with their experiments 
concentrating on the stability of the protein interactions on the intra-dimer interface, 
yielding a clear explanation of how AMPA receptors enter the desensitized state. 
Introducing mutations that destabilized protein interactions on the intra-dimer interface 
resulted in receptors that entered the desensitized state more rapidly, while introducing 
mutations that stabilized protein interactions on the intra-dimer interface resulted in 
receptors that desensitized significantly slower. Priel and colleagues, 2005, suggested that 
TARPs may utilize a similar mechanism and decreases steady-state desensitization of 
AMPA receptors by stabilizing the intra-dimer interface. 
In our attempt to understand the mechanism by which stargazin affects AMPA 
receptor desensitization, we prepared mutations on the intra-dimer interface of the AMPA 
receptor that produced moderate changes in onset of desensitization. Stargazin’s effects 
on steady-state desensitization were additive, or possibly synergistic, with mutations that 
stabilized the dimer interface E482A and K748A, but were occluded in the mutation 
N743D that destabilized the dimer interface. Stargazin was able to speed the recovery 
from desensitization for all constructs on the dimer interface. These results support our 
hypothesis that stargazin does not act by stabilizing the dimer interface, but rather by 
speeding AMPA receptor’s recovery from desensitization. 
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 7.1.2 Sites of association and efficacy between the AMPA receptor and stargazin 
located on the AMPA receptor side. 
In our attempt to identify areas important for association of stargazin and the AMPA 
receptor, we were guided by homology between AMPA receptors and kainate recepto s 
as well as crystal structure of the ligand-binding domain. As a result of our expe iments, 
we identified three areas on the AMPA receptor that include region downstream of helix 
H, region proximal to the membrane in the M4 linker and the intracellular loop 2 thatare 
candidate association sites with stargazin. 
The portion of the GluR1 crystal downstream of helix H that involves residues K693, 
G694 and K695 differs in structure from that of the kainate receptor, such that residues 
K693 and G694 are missing and residue K695 is substituted with aspartic acid (D) in 
GluR6. We mutated these lysine residues to alanines to preserve GluR1 spacing
(K693A/K695A) and deleted them to preserve GluR6 spacing (del(K693/G694)/K695D) 
(residues illustrated on Figure 7.1). The mutant construct del(K693/G694)/K695D 
expressed alone had a significantly slower rate of recovery from desensitization, 
indicating that introducing GluR6 spacing into GluR1 made the desensitization profile of 
GluR1 more like that of GluR6. Such spacing difference between AMPA and kainate 
receptors may also be a part of what prevents kainate receptors from associating with 
TARPs. 
When co-expressed with stargazin, both constructs presented with a striking lack of 
effect on AMPA receptor steady-state desensitization and recovery from desensitization, 
significantly decreased kainate efficacy but fully preserved trafficking. Results from 
del(K693/G694)/K695D construct, taken alone, are difficult to interpret because this 
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mutation introduces changes to the spacing and tertiary structure of the protein. The loss 
of effects of stargazin on AMPA receptor desensitization and decrease of eff ct on 
kainate efficacy, in the K693A/K695A construct that preserves GluR1 spacing suggests 
that this may be a site of extracellular association. However, because the effect of 
stargazin on receptor trafficking in this construct was preserved, we suggest that this 
mutant construct was still able to maintain the intracellular association responsible for 
trafficking. It is also possible that these mutations do not affect association of AMPA 
receptor pore-forming subunits with stargazin, but instead just alter the way the AMPA 
receptor transduces the effects of stargazin. 
Co-expression of the mutant construct E674R/P675Q at the end of helix G with 
stargazin resulted in a similar desensitization and kainate phenotype as del(K693/ 
G694)/K695D. The severe nature of this mutation, changing a negative charge to a 
positive at position 674 and removing a proline at position 675, would be expected to 
alter local tertiary structure of the protein. While it is possible that the E674R/P675Q 
actually forms an association with stargazin, it is more likely that this mutation affects the 
structure of the lower outer face of the AMPA receptor (by introducing tension at the end 
of helix G, therefore rearranging position of the residues downstream of helix H), an area 
identified by the K693A/K695A mutant as being important for stargazin function. 
The mutant construct in the M4 linker S784G/A789G, that had no significantly 
different phenotype when expressed alone, also resulted in significantly less effect of 
stargazin on steady-state desensitization, rate of recovery from desensitization, kainate 
efficacy but fully preserved trafficking. These data indicate that residu  S784 and A789 
may also participate in the extracellular association with stargazin (Figure 7.1). However, 
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because the effects of stargazin on trafficking are fully preserved in S784G/A789G 
construct we suggest that intracellular association responsible for trafficking is still 
maintained. It is also possible that the resulting loss of stargazin’s effects in this mutant is 
a result of diminished association located lower in the TM4 or decreased stargazin 
efficacy caused by the mutation. 
Co-expression of constructs carrying mutations of residues in the second intracellular 
loop of GluR1 (S588M and S591A) resulted in significantly decreased effects of 
stargazin on steady-state desensitization and kainate efficacy and fully preserved 
trafficking. Recent data indicates that the intracellular loop and intracellular N-terminus 
of stargazin are important for stargazin’s effects on AMPA receptor gating (Milstein and 
Nicoll, 2009). It is also possible that there are multiple intracellular associ tion sites 
between the AMPA receptor pore-forming subunits and stargazin with one being 
exclusively important for trafficking. Therefore it is possible that mutations in the second 
intracellular loop of the AMPA receptor interfere with the one of the intracellular 
association sites with stargazin, consistent with stargazin’s diminished effect on steady-
state desensitization and kainate efficacy.  
Mutations in helix K, K757M and D765G, on the lateral dimer interface/the lateral 
face of the receptor resulted in constructs with significantly slower rat  of recovery from 
desensitization. Although the desensitization deficits caused by these mutations 
(significantly slowed rate of recovery from desensitization) were completely rescued by 
stargazin’s effect on the recovery from desensitization, stargazin was unable to fully 
potentiate kainate currents in these constructs. Because we suspect that one of the 
association sites between stargazin and AMPA receptor is located in the M4 linker that 
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connects helix K with TM4, we suggest that residues in helix K do not directly associate 
with stargazin, but rather transduce its effects on the rest of AMPA receptor. It is possible 
that association with stargazin in the M4 linker causes a change in the positioning of 
helix K, therefore occluding the effects of these mutations on desensitization. We propose 
that stargazin alters protein conformation on the lateral dimer interface thus changing 
interactions between the two dimers. 
 
Figure 7.1: Possible sites of association with stargazin. Ribbon diagram illustrates a side 
view of the subunit, with the dimer interface pointing into the page and the outer face of 
the subunit pointing out of the page. Linkers connect the ligand-binding domain with TM 
regions. Stargazin is positioned in the lateral dimer interface where it could form contact 
with the M4 linker residues S784 and A789, area downstream of helix H, including 
residues K693 and K695, TM regions and the intracellular loop 2. 
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In summary, Figure 7.1 illustrates possible association sites between the AMPA 
receptor pore-forming subunit and stargazin. Our data suggests that stargazin is located 
on the lateral inter-dimer interface and forms a contact with residues S784 and A789 in 
the M4 linker, residues K693 and K695 downstream of helix H and possibly residues 
S588 and S591 in the second intracellular loop of AMPA receptor pore-forming subunit. 
7.1.3 Sites of association and efficacy between the AMPA receptor and stargazin 
located on the stargazin protein. 
Utilizing homology between class I TARPs and related proteins, we identified several 
residues in stargazin that are important for association with GluR1. These residues are 
concentrated near the plasma membrane in the first and second extracellular loops of
stargazin and include S36 in the proximal portion of the first extracellular loop, R99, 
S104, S105 and I106 in the distal portion of the first extracellular loop and Y155, I156 
and S157 in the proximal portion of the second extracellular loop of stargazin (illustrated 
in Figure 7.2). When mutated, these residues result in constructs that are unable to elicit 
stargazin’s full effects on desensitization and kainate efficacy. Because of th ir location 
near the membrane and a phenotype similar to that of S784G/A789G in the M4 linker of 




Figure 7.2:  Stargazin schematic indicating residues of interest in the extracellulr 
domains of stargazin. 
Polar residues important for stargazin’s effect on AMPA receptor desensitization 
and kainate efficacy.  
Cysteine residues possibly participating in the mutual disulfide bond. 
Cysteine residues that do not play a role in disulfide linkages. 
Conserved mannosylation motif GLWXXC crucial for stargazin’s function  
 
All members of the γ subunit family have a conserved mannosylation motif 
GLWXXC (Figure 7.2), the function of which is unknown. Loss of this motif (and 
presumably mannosylation) in distally related PMP22 results in loss of association with 
other proteins (Ervin et al., 2005), while the loss of N-linked glycosylation in γ1 does not 
affect its association with voltage-gated calcium channels (Arikkath et al., 2003). In our 
attempt to understand the function of this motif, we prepared two mutants W64A and 
H60F/W64A/R65L. W64A, which removed the tryptophan that would be directly 
mannosylated, resulted in a deceased effect of stargazin on AMPA receptor kainate 
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efficacy and recovery from desensitization. The H60F/W64A/R65L mutation, however, 
resulted in the loss of all of stargazin’s normal effects on the AMPA receptor, including a 
complete loss of trafficking. The only phenotype H60F/W64A/R65L demonstrated was a
slight but significant slowing of the rate of recovery from desensitization in GluR1 (as 
opposed to stargazin’s normal effect on speeding of recovery). This change in rec pto  
kinetics suggests that H60F/W64A/R65L remains associated with GluR1 on the cell 
surface. It is, however, possible that interfering with the conserved GLWXXC motif does 
indeed alter the association of stargazin with AMPA receptors. Future experiments with 
surface biotinylation and western blots should be able to elucidate if the 
H60F/W64A/R65L construct is indeed associated with GluR1. 
Two cysteine residues conserved throughout the γ subunit family (C67 and C77 in γ2) 
are crucial for stargazin’s function and possibly participate in the mutual disulfi e bond 
(Figure 7.2). Although the mutant construct C77A is unable to affect AMPA receptor 
desensitization or kainate efficacy, it is able to increase receptor trafficking, in contrast to 
C67A that appeared to be non-functional. It is possible that because C67 is also a part of 
the GLWXXC motif, the resulting loss of function is related to the motif rather than he 
loss of a disulfide bond. However, because both constructs lost all effects on AMPA 
receptor desensitization and kainate efficacy, we suggest that these residu s participate in 
a disulfide bond that is necessary for the proper tertiary structure of the firs extracellular 
loop and for stargazin function. As an alternative explanation, it is also possible that these 
cysteine residues participate in bonding with other proteins, as observed in 
immunoglobulins (Underdown et al., 1977) important for AMPA receptor function. 
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While examining all the stargazin mutations described in this dissertation, we 
identified only three with a profound loss of stargazin’s effect on AMPA receptor steady-
state desensitization, kainate efficacy and trafficking - C67A, H60F/W64A/R65L and 
∆212 (described in chapter 1). Two of these mutant stargazin constructs 
(H60F/W64A/R65L and ∆212) slightly but significantly slowed the rate of recovery from 
desensitization in GluR1, in contrast to the normal effect of stargazin on speeding the rate 
of recovery from desensitization. These results suggest that although these constructs lost 
virtually all of the stargazin’s function, they were still able to associate at he surface and 
it is possible that the opposite effect on the recovery from desensitization occurs be ause 
the non-functional stargazin construct sterically hinders normal AMPA receptor function. 
7.1.4 Effects of stargazin on kainate efficacy. 
Preliminary results from our laboratory suggest that the effects of stargazin on kainate 
efficacy consist of at least two components. Approximately 30% of the increase in 
kainate currents is due to stargazin’s effect on kainate desensitization. The atur  of the 
other effect is unclear. However, we suspect that it involves increased gating in the 
presence of kainate. It is of interest to note that, while performing the experiments to 
locate the association site between the AMPA receptors and stargazin, we observed that 
many mutations on the AMPA receptor were able to eliminate stargazin’s effect on 
AMPA receptor glutamate desensitization, but not the effect on kainate efficacy. Even in 
GluR1 mutations that presented with loss of stargazin’s effect on glutamate 
desensitization including K693A/K695A, S784G/A789G and mutations in the 2nd 
intracellular loop of GluR1, which was interpreted as the loss of an association, the effect 
on kainate efficacy was partially preserved. We do not have the data to determin  
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whether the partial loss of kainate effect in these mutations resulted from increased 
kainate desensitization or decreased gating. However, based on the loss of the stargazin’s 
effects on glutamate desensitization in these mutations, we suspect that thepartial loss of 
kainate efficacy results from a loss of stargazin’s effect on kainate desensitization. These 
results therefore suggest that stargazin’s effects on kainate gating is mostly preserved in 
all of these mutants. Because mutation of stargazin residues proximal to the membran  in 
the 2nd extracellular loop seems to affect kainate gating, we suggest that residues 
important for stargazin’s effects on kainate gating are located in the transmembrane 
regions and are associated with the AMPA receptor ion channel. 
7.2  What we learned about the AMPA receptor from our experiments. 
7.2.1 Residues important for AMPA receptor recovery from desensitization are loc t d 
in helices B and K as well as the M1 linker and intracellular loop 2 
Previous experiments on the intra-dimer interface elucidated the mechanism involved 
in desensitization onset, but searches there or in loop 1 and helix G did not find any 
residues that affected the rate of recovery from desensitization (Horning a d Mayer, 
2004). Although the mechanism of desensitization onset has been elucidated, the 
mechanism of recovery from desensitization is still unknown. Here we present a series of 
mutations in the lateral dimer interface, M1 linker and first intracellular oop that affect 
the rate of recovery from desensitization. 
In our search for residues important in association of stargazin and AMPA receptor, 
we identified several residues located on the lateral dimer interface/the lateral face of the 
receptor whose amino acid side chains were exposed and pointing out of the protein. 
When mutated to their corresponding residues in GluR6, these constructs in helix K 
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(K757M and D765G) presented with significantly slower rate of recovery from 
desensitization. Because these residues are located on the lateral dimer interface, it is 
possible that recovery from desensitization involves conformational rearrangeme ts on 
the lateral dimer interface. Because stargazin’s main effect is on the recovery from 
desensitization, the fact that it was able to fully rescue desensitization defcits in helix K 
mutants argues in support of this hypothesis.  
Mutant construct K501A/K502A in the M1 linker also presented with a slower rate of 
recovery from desensitization. These residues are located in the lower portion of the 
crystal structure below the intra-dimer interface. However, because the artificial linker 
was introduced between the M1 and the M3 linkers, the position of these residues may be 
somewhat distorted in a crystal (illustrated in Figure 7.3). This mutation presented with a 
phenotype similar to helix B mutation K434T. Therefore we suggest that both of these 
residues at the very beginning of the M1 linker and the top of helix B participate in 
coordinating the recovery from desensitization, which must include the reconstitution of 
the dimer interface. The top of helix B, which sits immediately above helix J in the 
beginning of linker 1 (illustrated on Figure 7.3), which is low in the intra-dimer interfac , 
would be logically placed to guide this reconstitution. One would predict that stargazin 
would have little effect on steady-state desensitization in AMPA receptors that had 
difficulty reconstituting their dimer interface, which is what we observed with both of 
these constructs. Interestingly, preliminary data from mutations in loop 2 (data not 
shown) of the AMPA receptor suggest that this region may also participate in the 
mechanism of recovery from desensitization. 
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Figure 7.3: Areas of the AMPA receptor important for recovery from desensitization. 
Ribbon diagram represents a side view of the crystallized ligand-binding domain of 
GluR2 subunit, with the dimer interface pointing to the right of the page and the outer 
face of the subunit pointing to the left of the page. The arrow indicates the direction of 
the movement that the upper portion of the clamshell undergoes during recovery from 
desensitization and reconstitution of the intra-dimer interface. 
 
The function of the intracellular loops of the AMPA receptor has received little 
attention in the literature. While trying to locate residues that might be important for 
association with stargazin, we identified three residues in the second intracellular loop of 
GluR1, S588, S591 and G594, that when mutated to their corresponding residues in 
GluR6, presented with slowed recovery from desensitization. Mutation of R595 to 
alanine or serine resulted in a non-functional construct, suggesting that this residueis 
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critical for ion channel function. It is therefore our interpretation that phenotypes 
observed with mutations at G594 most probably result from interference with R595.  
However, residue S588 in particular is important for recovery from desensitization. 
Because the recovery from desensitization must be coupled to opening of the ion pore, it 
is possible that S588, located 3 amino acids downstream from the re-entrant loop, is 
involved in this process. 
7.2.2 Residues proximal to the membrane in the M1 and M4 linker regions control 
gating of AMPA receptor 
AMPA receptor linkers are responsible for transducing the conformation of the 
ligand-binding core to the ion channel pore (Mathur et al., 1997). Because linkers are 
crucial for channel gating in voltage-gated ion channels, it is not surprising we identified 
two mutations that affected AMPA receptor gating.  
 A518S/Y519P and V788I mutant constructs in M1 and M4 linkers, respectively, 
presented with significantly decreased steady-state desensitization and significantly 
increased kainate efficacy, without any effect on the rate of desensitization onset or 
recovery. Because the kinetics of steady-state desensitization are shaped by the rates of 
desensitization onset and recovery, the change in steady-state desensitization n these 
constructs must have resulted from gating changes. These gating changes possibly 
resulted from either increased mean open time of the receptor or a shift to a higher 
conductance state. Because whole-cell recordings are limited in their ability to observe 
gating changes, single-channel recordings will be necessary to prove if these constructs 
indeed have higher conductance. 
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7.2.3 Mutations in helix D on the dimer interface of GluR1 present with different 
phenotypes compared to the same mutations in GluR2. 
GluR1 and GluR2Q homomeric receptors differ in their desensitization profile, such 
that GluR2 desensitizes more slowly and to a lesser degree than GluR1 (99.5% for GluR1 
and 98.5% for GluR2Q). While attempting to understand the effects of stargazin on 
desensitization of AMPA receptors, we prepared mutations that were previously 
described in GluR2 as affecting AMPA receptor steady-state desensitization and the rate 
of desensitization onset. Although most of the crystallographic work has been done in the 
GluR2 subunit, homomeric GluR2Q receptors do not occur endogenously, while 
homomeric GluR1flip subunits produce robust responses and are endogenously 
expressed.  
Two of the four previously described mutations on the dimer interface presented with 
different phenotypes. The L479A mutation in GluR2 had decreased steady-state 
desensitization and slowed rate of desensitization onset (Horning and Mayer, 2004), 
while in GluR1 it had no distinguishable phenotype. Mutation E482A was previously 
shown to speed the rate of desensitization onset and increase steady-state desensitization 
of GluR2 (Horning and Mayer, 2004), while in GluR1 it had an opposite effect on 
desensitization properties with significantly slowed rate of desensitization onset and 
decreased steady-state desensitization. Such discrepancies are probably caused by the 
innate differences between two subunits. 
These same two mutations on helix D, L479A and E482A, had an unexpected effect 
on negative cooperativity between glutamate and trichlormethiazide in GluR1, which as 
not observed in the GluR2 background. It appeared that, as more glutamate binds, the 
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ability of TCM to block desensitization in these mutants was reduced. A similar effect is 
seen in flop splice variants (the flip/flop cassette is known to contain part of the 
cyclothiazide binding site). However, these mutations are located in a region distinct 
from this alternative splice site. Because part of the binding site for TCM is located on 
the dimer interface and is coordinated by the residues on the β strand 7, downstream of 
helix D (Sun et al., 2002), it is possible that mutation of the residues in helix D alter the 
conformation or exert tension on β strand 7 during glutamate binding, thus decreasing the 
affinity for TCM in GluR1. 
7.2.4 Existence of two desensitized states in AMPA receptors 
While modeling AMPA receptor desensitization onset and recovery, it was previously 
observed that both rates are best fit with two exponentials in neurons (Patneau and 
Mayer, 1991; Raman and Trussell, 1992), suggesting that AMPA receptors transition 
between two desensitized states (Robert and Howe, 2003). While working on this project 
we made an observation that in any mutation with reduced steady-state desensitizatio  
(E482A, K748A, A518S/Y519P and V788I) effects of stargazin were always synergistic. 
However, in mutations that presented with more steady-state desensitization (N743D and 
K501A/K502A) effects of stargazin on steady-state desensitization were decreas d or 
occluded. These results suggest two different desensitized states exist in the AMPA 
receptor. Because we suspect that N743D mutant construct is desensitized at rest, our
data supports the hypothesis that one of these states is not agonist bound. Because 
stargazin is able to potentiate peak responses to glutamate even in the mutations with 
increased steady-state desensitization (N743D and K501A/K502A), we suggest that it is 
can influence both of these states. 
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7.3 Limitations of our studies 
Although we were able to identify possible sites of association between AMPA 
receptors and stargazin, electrophysiological experiments cannot definiiv ly prove that 
these are sites where stargazin and the pore-forming subunits of the AMPA receptor 
make contact with one another. We anticipated that the loss of extracellular association 
would present with a phenotype observed in the chimeric exchange between stargazin 
and γ5 Ex(26-103) (Figure 1.11), where most of the stargazin’s effect on kainate efficacy 
and desensitization would be lost and trafficking effects would be only modestly 
decreased. However, none of the mutations we observed presented with this exact 
phenotype. Surprisingly, the effects of stargazin on kainate efficacy were always at least 
partially preserved with mutation in the AMPA receptor. We attribute the decreased 
effect of stargazin on kainate efficacy as the loss of the effect on kainate desensitization. 
Therefore, this result suggests that the effects of stargazin on kainate gating could be a 
result of interaction in the transmembrane regions rather than the purelyextracellular 
association as we previously thought. Alternatively, it may be that multiple points of 
association in the extracellular domains are involved. The largest reduction in kaiate 
efficacy was observed with the combined mutations proximal to the plasma membrane in 
the first extracellular loop of stargazin. 
We also anticipated that the loss of intracellular association between the AMPA
receptor and stargazin would present with a phenotype similar to the deletion of the C-
terminal tail ∆212 (Figure 1.11), where the effects of stargazin on trafficking would be 
entirely lost, while the effects on desensitization and kainate efficacy would be only 
slightly decreased. However, none of the mutations on the AMPA receptor or stargazin 
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generated a similar phenotype. Therefore we suggest that there may be multiple 
intracellular associations, where one is exclusively important for trafficking, while the 
others are important for effects of stargazin on AMPA receptor desensitization, gating 
and kainate efficacy. 
 To answer the question if the effects of mutations were a result of association or 
efficacy, we will require further experiments with surface biotinylation and western blots. 
It is also possible that combining mutations that are candidate extracellular association 
sites (S784G/A789G with K693A/K695A) would result in a phenotype similar to that 
observed in Ex(26-103). If so, combing the extracellular association site mutations with 
intracellular loop 2 association site mutations could result in a protein that presents with 
complete loss of desensitization and kainate effects of stargazin on AMPA receptor. Such 
combinations of the extracellular and intracellular mutations might be able to completely 
break all association between the two proteins that we will be able to confirm 
electrophysiologically and with surface biotinylation. 
In certain mutations outside-out patch and/or single-channel recordings will be 
necessary to prove suggested changes in gating. Patch recordings would also strengthen 
our findings regarding mechanism of recovery from desensitization. The standard 
protocol in the AMPA receptor field for measuring recovery from desensitization is to 
utilize twin-pulse recordings in patches. Instead we used a measurement that is 
proportional to the rate of recovery from desensitization, the on-rate of the TCM in the 
presence of glutamate. To definitively prove the effects of the mutations on therecovery 
from desensitization we may need to perform twin-pulse recordings in patches. 
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Several mutations (K693A/K695A, S588M and S591A) presented with decreased 
trafficking. We used current density as a proxy for trafficking, based on our previous 
demonstration that the levels of surface expression are correlated with changes in current 
density (Turetsky et al., 2005). However, the decreases in trafficking in mutations we 
made could have also resulted from decreased channel conductance. Whole-cell 
recording cannot distinguish between the actual decreases in receptor trafficking vs. the 
decrease in conductance. We also know that stargazin potentiates AMPA receptor 
trafficking; however, because stargazin potentiated trafficking of several mutants 
(K693A/K695A, S588M and S591A) several fold more than control GluR1, it is possible 
that in some of these mutations stargazin was also able to also elicit an effect on channel 
conductance. Therefore, to prove that trafficking of these mutants was a result of lower 
surface expression, we will need to perform single-channel recordings to make sure that 
the channel conductance in these mutants did not change, in conjunction with surface 
biotinylation experiments to show that the amount of AMPA receptors at the surface is 
decreased. 
Although our studies were limited in understanding of all of the molecular 
mechanism underlying the effects of the mutations, we were still able to suggest areas of 
AMPA receptor important for recovery from desensitization and areas of association 
between AMPA receptor and stargazin. 
7.4 Significance of our studies 
Post-synaptic AMPA receptors play an important role in mediating fast excitatory 
neurotransmission in the mammalian CNS. Therefore AMPA receptor desensitization has 
a considerable effect on shaping the time course and amplitude of the synaptic 
 125
transmission. Current classes of drugs that are used for potentiation of synaptic 
transmission, AMPAkines, bind at the intra-dimer interface, therefore blocking the onset 
of desensitization (Lynch, 2006). Such a crude effect sometimes has an unwanted side 
effect of seizures.  
Several non-competitive AMPA receptor antagonists (such as Talampanel) wer  
suggested for use during the ischemic events to prevent the excitotoxicity (Tomillero and 
Moral, 2008; Luszczki, 2009). However, most of these drugs have the unwanted side 
effect of profound memory loss. Therefore, identifying areas of the AMPA receptor that 
mediate recovery from desensitization and a better understanding of the mec anism of 
recovery from desensitization could elucidate new targets for rational drug desi n. Such 
drugs could act on the lateral inter-dimer interface to either speed the rate of ecovery 
from desensitization, therefore potentiating synaptic transmission, or to slow the rate of 
recovery from desensitization during ischemic events to ameliorate the neurotoxic effects 
of glutamate. Because stargazin has a large extracellular portion that plays such an 
important function in AMPA receptor physiology, it could also potentially be a candid te 
for rational drug design. Overall our studies provide a new insight into AMPA receptor 
physiology that is beneficial for scientific and medical fields. 
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ABSTRACT:  AMPA receptors mediate the majority of neurotransmission in the CNS. 
One of the most important properties of AMPA receptors is their quick and profound 
desensitization in the presence of glutamate. Although, the mechanism of AMPA 
receptor desensitization onset has been elucidated and involves breaking of the protein 
interactions on the dimer interface in response to agonist binding, the mechanism of 
recovery from desensitization remains unknown. When co-expressed with the auxiliary 
subunit stargazin AMPA receptor functional properties are affected: steady-state 
desensitization is decreased, recovery from desensitization is faster, kainate efficacy is 
increased and deactivation is slowed. The mechanism of stargazin’s action on AMPA 
receptor and their sites of association remain unknown. Previous studies suggested that 
stargazin decreases AMPA receptor steady-state desensitization by stabilizing the dimer 
interface. However, in our studies we were able to demonstrate that stargazin’s effect on 
steady-state desensitization in mutations that stabilize the dimer interface is additive, 
while its effects on steady-state desensitization in a mutant that destbilized the dimer 
interface is occluded, indicating that stargazin does not act by stabilizing the intra-dimer 
interface, but instead destabilizes the desensitized state and speeds the recovery from 
desensitization. To identify residues that may be part of association between the AMPA 
pore-forming subunits and stargazin we were guided by the homology between AMPA 
and kainate receptors and the crystal structure of the LBD. We identified res dues 
downstream of helix H (K693 and K695) and in the M4 linker (S784 and A789) that 
when co-expressed with stargazin presented with loss of it effects, suggestin  tha  these 
residues may participate in the association with stargazin. Based on our data we were also 
able to propose a mechanism for recovery from desensitization that includes resiues in 
helix B (K434) and the M1 linker (K501 and K502). Utilizing a similar approach in 
stargazin we were able to identify areas that are necessary for its association with the 
AMPA receptors, including polar residues proximal to the plasma membrane in the 1st 
and 2nd extracellular loops and others that are crucial for its function, the conserved motif 
GLWXXC and conserved cysteine residues at positions 67 and 77.  
